Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 40340. Отображено 100.
05-01-2012 дата публикации

Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme

Номер: US20120004206A1

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Подробнее
05-01-2012 дата публикации

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE

Номер: US20120004213A1
Принадлежит: Forest Laboratories Holdings Ltd

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

Подробнее
19-01-2012 дата публикации

Taspase1 inhibitors and their uses

Номер: US20120015990A1
Автор: Emily Cheng, James Hsieh
Принадлежит: Washington University in St Louis WUSTL

Provided herein are small molecule inhibitors of Taspase1 and methods of using the small molecule inhibitors of Taspase1 to treat neoplasm in subjects in need thereof.

Подробнее
26-01-2012 дата публикации

Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System

Номер: US20120020915A1

Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Подробнее
26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1
Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее
26-01-2012 дата публикации

Heterocyclic antagonists of prostaglandin d2 receptors

Номер: US20120022119A1
Принадлежит: Amira Pharmaceuticals Inc

Described herein are heteroaryl compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Подробнее
02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее
02-02-2012 дата публикации

Synthesis of enone intermediate

Номер: US20120029199A1
Принадлежит: Harvard College

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.

Подробнее
02-02-2012 дата публикации

Synthesis of substituted-3-aminopyrazoles

Номер: US20120029204A1
Принадлежит: Schering Corp

The present invention discloses a process of preparing compound of formula (I): wherein A, M, and Z are as defined herein. An example of a compound of formula (I) is 3-amino-1-methyl-1H-1′H-4,4′-bispyrazole.

Подробнее
09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1
Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее
09-02-2012 дата публикации

Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies

Номер: US20120035230A1
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
22-03-2012 дата публикации

Pyrazole oxadiazole derivatives as s1p1 agonists

Номер: US20120071460A1
Принадлежит: MERCK SERONO SA

The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R 1 , R 2 and R 3 are as defined in the description.

Подробнее
22-03-2012 дата публикации

Estrogen receptor modulators and uses thereof

Номер: US20120071535A1
Принадлежит: Aragon Pharmaceuticals Inc

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

Подробнее
12-04-2012 дата публикации

Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same

Номер: US20120088746A1
Принадлежит: PFIZER INC

Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

Подробнее
12-04-2012 дата публикации

Five-membered heterocycles useful as serine protease inhibitors

Номер: US20120088758A1
Принадлежит: Bristol Myers Squibb Co

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R 3 , R 4 , R 6 , R 11 , X 1 , X 2 , and X 3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Подробнее
19-04-2012 дата публикации

Organic Compounds Having Cooling Properties

Номер: US20120095042A1
Автор: Stefan Michael Furrer
Принадлежит: Givaudan SA

Provided are compounds of formula (I) wherein m is 0, 1 or 2; R I is a mono- or bicyclic heterocyclic ring system including one, two or three heteroatoms selected from nitrogen, sulphur and oxygen; R 2 is selected from hydrogen, methyl and ethyl; I) R 3 is hydrogen, methyl, or ethyl; and R 4 and R 5 are independently selected from ethyl and isopropyl; and R 3 , R 4 and R 5 together have at least 6 carbon atoms: or II) any two or all of R 3 , R 4 and R 5 form together with the carbon atom to which they are attached 3-para-menthyl, bornyl, or adamantyl; having cooling properties, their use as cooling agent and compositions including them.

Подробнее
10-05-2012 дата публикации

Compound inhibiting in vivo phosphorus transport and medicine containing the same

Номер: US20120115851A1
Принадлежит: Kyowa Hakko Kirin Co Ltd

An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R 5 represents optionally substituted aryl or the like, Z represents —N═CHR 6 R 7 or the like, R 6 and R 7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R 101 and R 102 together form ═O, and R 103 and R 104 represent H, or R 101 and R 104 together from a bond, and R 102 and R 103 together form a bond.

Подробнее
10-05-2012 дата публикации

N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

Номер: US20120115915A1
Принадлежит: Harvard College

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

Подробнее
17-05-2012 дата публикации

Compounds, Compositions and Methods for Modulating Uric Acid Levels

Номер: US20120122780A1
Принадлежит: Ardea Biociences Inc

Described herein are compounds useful in the reduction of blood uric acid levels, formulations containing them and methods of making and using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

Подробнее
31-05-2012 дата публикации

Substituted Esters as Cannabinoid-1 Receptor Modulators

Номер: US20120135975A1
Принадлежит: Merck and Co Inc

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

Подробнее
07-06-2012 дата публикации

Integrin-linked kinase inhibitors

Номер: US20120142702A1

A number of compounds and use of the compounds in a method for treating or preventing cancer in a subject by administering to the subject a pharmaceutical composition including a compound of formula I or a pharmaceutically acceptable salt thereof are described. The compounds can also be used to inhibit integrin-linked kinase in a cell, which has an effect on the Akt signaling pathway.

Подробнее
14-06-2012 дата публикации

Inhibition of p38 kinase activity using substituted heterocyclic ureas

Номер: US20120149706A1
Принадлежит: Individual

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.

Подробнее
05-07-2012 дата публикации

Co-crystals of tramadol and coxibs

Номер: US20120172398A1
Принадлежит: Laboratorios del Dr Esteve SA

The present invention relates to co-crystals of tramadol and co-crystal formers selected from NSAIDs/coxibs, processes for preparation of the same and their uses in pharmaceutical formulations for the treatment of pain.

Подробнее
12-07-2012 дата публикации

Pyrimidine derivatives and analogs, preparation method and use thereof

Номер: US20120178915A1
Автор: Lifeng Xu
Принадлежит: Individual

This invention relates with the arylheterocycle-fused pyrimidines, derivatives and analogs of formula I: or stereoisomers, tautoers, prodrugs, pharmaceutically acceptable salts, complex salts or solvates thereof, wherein: A-cycle is of 3-8 saturated or unsaturated arylheterocycles or aliheterocyclic, containing 1-4 heteroatoms, B-cycle 5-8 member saturated or unsaturated heterocycle containing 1-4 heteroatoms; X 1 , X 2 , X 3 , X 4 are, independently at each occurrence, C, O, S, Se, N and P elements; R 1 , R 2 , R 3 is a substituent containing alicyclic group, arylcycle group, heterocyclic group, adamantane alkyl, adamantane heterocycle, adamantane analogs, sugar group, hydroxyl group, amino acid group or a combination of the above substituents. This invention also relates with their preparative methods and applications.

Подробнее
19-07-2012 дата публикации

Novel compounds

Номер: US20120184553A1
Принадлежит: Glaxo Group Ltd

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, particularly Parkinson's disease and Alzheimer's disease.

Подробнее
26-07-2012 дата публикации

Fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor

Номер: US20120190845A1

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X 1 -X 5 , R 5 -R 8b , Z 1 -Z 2 and Ar 1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
09-08-2012 дата публикации

Processes relating to the alkylation of pyrazoles

Номер: US20120203009A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

The present invention relates to processes for the preparation of a compound of formula (I) comprising reacting a compound of formula (IV) with a compound of formula III or (IIIA) in the presence of an acid; wherein R 1 is C 1 -C 4 haloalkyl; R 2 is optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; R 3 is methyl or ethyl; R 4 is hydrogen, optionally substituted alkyl, optionally substituted aryl or optionally substituted heteroaryl; and n is 0 or 1.

Подробнее
23-08-2012 дата публикации

3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators

Номер: US20120213791A1
Принадлежит: ASTEX THERAPEUTICS LTD

The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof, and combinations thereof with other anti-cancer agents, for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
30-08-2012 дата публикации

Guanidine-containing compounds useful as muscarinic receptor antagonists

Номер: US20120219509A1
Принадлежит: Theravance Inc

The invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R 1-3 , R 5-7 , a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.

Подробнее
30-08-2012 дата публикации

2-phenylethylamino derivatives as calcium and/or sodium channel modulators

Номер: US20120220592A1
Принадлежит: Newron Pharmaceuticals SpA

2-Phenylethylamino substituted carboxamide derivatives and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies are presented.

Подробнее
06-09-2012 дата публикации

Compositions and methods useful for treating diseases

Номер: US20120225851A1
Принадлежит: Eutropics Pharmaceuticals Inc

The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula Ia′, Ib′, Ic′, or II′ (referred to as a group as BH3Is) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MCL-1. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds or Formula Ia, Ib, Ic, or II in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula Ia′, Ib′, Ic′, or II′. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.

Подробнее
06-09-2012 дата публикации

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Номер: US20120225890A1
Принадлежит: ProteoTech Inc

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
20-09-2012 дата публикации

Iodine radiolabelling method

Номер: US20120237444A1
Автор: Michelle Avory
Принадлежит: Individual

The present invention provides a novel method of labelling biological targeting molecules (BTMs) of interest with radioiodine. Also provided are novel radioiodinated BTMs prepared using the method, as well as radiopharmaceutical compositions comprising such radioiodinated BTMs. The invention also provides radioiodinated intermediates useful in the method, as well as in vivo imaging methods using the radioiodinated BTMs.

Подробнее
04-10-2012 дата публикации

Compounds, compositions, and methods for the treatment of beta-amyloid diseases and synucleinopathies

Номер: US20120252858A1
Принадлежит: ProteoTech Inc

Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of β-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
11-10-2012 дата публикации

Dual-acting pyrazole antihypertensive agents

Номер: US20120259113A1
Принадлежит: Theravance Inc

In one aspect, the invention relates to compounds having the formula: wherein: Ar, Z, R 3 , R 4 and R 5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT 1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Подробнее
11-10-2012 дата публикации

Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides

Номер: US20120259120A1
Принадлежит: Thimma Rawalpally, Thomas Cleary, Yaohui Ji

The present invention provides novel methods for preparing 5-(trifluoromethoxy)-1H-3-indazolecarboxylic acid (3), which is a useful precursor for the preparation of bicyclic-5-trifluoromethoxy-1H-indazole-3-carboxylic acid amides of Formula (1). Compounds of Formula (1) are active as agonists and partial agonists of the nicotinic α-7 receptor and are being studied for their use in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. The present methods are useful for preparing compound (3) on scale up levels.

Подробнее
25-10-2012 дата публикации

Adamantyl diamide derivatives and uses of same

Номер: US20120270873A1
Принадлежит: H Lundbeck AS

The present invention provides adamantyl-diamide derivatives of formula (I): wherein R 1 and R 2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.

Подробнее
03-01-2013 дата публикации

Pyrazole derivatives as protein kinase modulators

Номер: US20130005702A1
Принадлежит: Cancer Research Technology LTD

The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.

Подробнее
14-02-2013 дата публикации

PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE

Номер: US20130039906A1
Принадлежит: Genentech Inc

Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 1 and R 2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Подробнее
14-02-2013 дата публикации

Therapeutic agent and preventative agent for alzheimer's disease

Номер: US20130041158A1
Принадлежит: TORAY INDUSTRIES INC

A therapeutic agent or prophylactic agent for Alzheimer's disease has an effect to inhibit or delay the progress of Alzheimer's disease and exhibits a long-lasting therapeutic effect on Alzheimer's disease even when used for a long period of time. The therapeutic agent or prophylactic agent for Alzheimer's disease includes as an effective ingredient a cyclohexane derivative exemplified by the formula below, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

Подробнее
07-03-2013 дата публикации

Synthesis of substituted pyrazoline carboxamidine derivatives

Номер: US20130060041A1

This invention relates to organic chemistry, in particular to processes for the preparation of pyrazoline carboxamidine derivatives of formula (I), known as potent 5-HT6 antagonists. The invention also relates to novel intermediates of these compounds. wherein the symbols have the meanings given in the description.

Подробнее
21-03-2013 дата публикации

Polycyclic compounds as lysophosphatidic acid receptor antagonists

Номер: US20130072490A1
Принадлежит: Amira Pharmaceuticals Inc

Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.

Подробнее
21-03-2013 дата публикации

PYRAZOLECARBOXAMIDE DERIVATIVES AND THEIR USE AS MICROBIOCIDES

Номер: US20130072535A1
Принадлежит: SYNGENTA CROP PROTECTION LLC

Compounds of Formula (I) wherein Ris C-Calkyl or C-Chaloalkyl; Ris C-Calkyl; Ris hydrogen or halogen; Ris hydrogen, C-Calkyl or C-Chalogenalkyl; Ris hydrogen, halogen, C-Calkyl or C-Chalogenalkyl; Ris hydrogen, halogen, C-Calkyl, C-Calkenyl or C-Calkinyl; Ris hydrogen, halogen, C-Calkyl, C-Calkenyl, C-Calkinyl, C-Ccycloalkyl-C-Calkinyl, halophenoxy, halophenyi, C-Chaloalkyl, C-Chaloakoxy, C-Chaloalkenyl, or C-Chaloalkenyloxy; Ris hydrogen, halogen, C-Calkyl, C-Calkenyl or C-Calkinyl; with the provisio that at least one of R, Rand Ris different from hydrogen; n is 0 or 1, are suitable for use as microbriocides. 2. A compound of formula I according to claim 1 , wherein{'sub': '1', 'Ris difluoromethyl, trifluoromethyl or methyl,'}{'sub': '2', 'Ris methyl;'}{'sub': '3', 'Ris hydrogen or fluoro;'}{'sub': '4', 'Ris methyl;'}{'sub': '5', 'Ris hydrogen or methyl;'}n is 0; and{'sub': 6', '7', '8, 'R, Rand Rindependently from each other, are hydrogen or chloro.'}3. A compound of formula I according to claim 2 , wherein{'sub': '5', 'Ris hydrogen.'}4. A compound of formula I according to claim 1 , wherein{'sub': '1', 'Ris difluoromethyl or trifluoromethyl;'}{'sub': '2', 'Ris methyl;'}{'sub': '3', 'Ris hydrogen;'}{'sub': '4', 'Ris methyl;'}{'sub': 6', '7', '8, 'R, Rand Rare, independently from each other, hydrogen or halogen.'}5. A compound of formula I according to claim 4 , wherein R claim 4 , Rand Rare claim 4 , independently from each other claim 4 , hydrogen or chloro claim 4 , with the proviso that at least one of R claim 4 , Rand Ris different from hydrogen.6. A compound of formula I according to claim 1 , wherein{'sub': '5', 'Ris hydrogen.'}7. A compound of formula I according to claim 1 , wherein{'sub': 1', '1', '4, 'Ris C-Chaloalkyl;'}{'sub': 2', '1', '4, 'Ris C-Calkyl;'}{'sub': '3', 'Ris hydrogen;'}{'sub': 4', '1', '4, 'Ris C-Calkyl;'}{'sub': '5', 'Ris hydrogen;'}n is 0 or 1;{'sub': '6', 'Ris hydrogen or halogen;'}{'sub': 7', '8, 'Ris halogen; and Ris hydrogen or ...

Подробнее
21-03-2013 дата публикации

PYRAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY

Номер: US20130072536A1
Принадлежит: Synta Pharmaceuticals Corp.

Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. 179-. (canceled)81. The compound of claim 80 , wherein Ris an optionally substituted phenyl group.82. The compound of claim 81 , wherein Ris substituted with one or more group represented by R claim 81 , wherein R claim 81 , for each occurrence claim 81 , are independently an optionally substituted alkyl claim 81 , an optionally substituted alkenyl claim 81 , an optionally substituted alkynyl claim 81 , an optionally substituted cycloalkyl claim 81 , an optionally substituted cycloalkenyl claim 81 , an optionally substituted heterocyclyl claim 81 , an optionally substituted aryl claim 81 , an optionally substituted heteroaryl claim 81 , an optionally substituted aralkyl claim 81 , an optionally substituted heteraralkyl claim 81 , halo claim 81 , cyano claim 81 , nitro claim 81 , guanadino claim 81 , a haloalkyl claim 81 , a heteroalkyl claim 81 , alkoxy claim 81 , haloalkoxy claim 81 , —NRR claim 81 , —OR claim 81 , —C(O)R claim 81 , —C(O)OR claim 81 , —C(S)R claim 81 , —C(O)SR claim 81 , —C(S)SR claim 81 , —C(S)OR claim 81 , —C(S)NRR claim 81 , —C(NR)OR claim 81 , —C(NR)R claim 81 , —C(NR)NRR claim 81 , —C(NR)SR claim 81 , —OC(O)R claim 81 , —OC(O)OR claim 81 , —OC(S)OR claim 81 , —OC(NR)OR claim 81 , —SC(O)R claim 81 , —SC(O)OR claim 81 , —SC(NR)OR claim 81 , —OC(S)R claim 81 , —SC(S)R claim 81 , —SC(S)OR claim 81 , —OC(O)NRR claim 81 , —OC(S)NRR claim 81 , —OC(NR)NRR claim 81 , —SC(O)NRR claim 81 , —SC(NR)NRR claim 81 , —SC(S)NRR claim 81 , —OC(NR)R claim 81 , —SC(NR)R claim 81 , —C(O)NRR claim 81 , —NRC(O)R claim 81 , —NRC(S)R claim 81 , —NRC(S)OR claim 81 , —NRC(NR)R claim 81 , —NRC(O)OR claim 81 , —NRC(NR)OR claim 81 , —NRC(O)NRR claim 81 , —NRC(S)NRR claim 81 , — ...

Подробнее
28-03-2013 дата публикации

THROMBOPOIETIN MIMETICS

Номер: US20130078213A1
Принадлежит:

Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. 150-. (canceled)52. The method of wherein Q is —COOH claim 51 , which is the compound 3′-{N′-[1-(3 claim 51 ,4-Dimethylphenyl)-3-methyl-5-oxo-1 claim 51 ,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof.53. The method of wherein Q is tetrazol-5-yl claim 51 , which is the compound 3-{N′-[1-(3 claim 51 ,4-dimethylphenyl)-3-methyl-5-oxo-1 claim 51 ,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl or a pharmaceutically acceptable salt thereof.54. The method of wherein the compound is administered orally.55. The method of wherein the compound is administered parenterally.56. The method of further comprising co-administering a therapeutically effective amount of an agent selected from the group consisting of: a colony stimulating factor claim 51 , cytokine claim 51 , chemokine and an interleukin or cytokine receptor agonist or antagonist.57. The method of wherein the agent is selected from the group consisting of: G-CSF claim 56 , GM-CSF claim 56 , TPO claim 56 , M-CSF claim 56 , EPO claim 56 , Gro-beta claim 56 , IL-11 claim 56 , SCF claim 56 , FLT3 ligand claim 56 , LIF claim 56 , IL-3 claim 56 , IL-6 claim 56 , IL-1 claim 56 , NESP claim 56 , SD-01 claim 56 , IL-8 and IL-5.59. The method of wherein Q is —COOH claim 58 , which is the compound 3′-{N′-[1-(3 claim 58 ,4-Dimethylphenyl)-3-methyl-5-oxo-1 claim 58 ,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof.60. The method of wherein Q is tetrazol-5-yl claim 58 , which is the compound 3-{N′-[1-( ...

Подробнее
28-03-2013 дата публикации

N-[(HET)ARYLALKYL)] PYRAZOLE(THIO)CARBOXAMIDES AND THEIR HETEROSUBSTITUTED ANALOGUES

Номер: US20130079302A1
Принадлежит:

The present invention relates to fungicidal N-[(het)arylalkyl)]pyrazolecarboxamide or thiocarboxamide and their heterosubstituted analogues, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. 2. A compound according to wherein Xand Xindependently represent a chlorine or a fluorine atom.3. A compound according to wherein Y represents methyl.4. A compound according to wherein T represents O.5. A compound according wherein B represents a substituted or non-substituted phenyl ring; a substituted or non-substituted naphthyl ring; a substituted or non-substituted pyridyl ring; a substituted or non-substituted thienyl ring; or a substituted or non-substituted benzothienyl ring; preferably a substituted or non-substituted phenyl ring or a substituted or non-substituted 2-pyridyl ring.6. A compound according to wherein X independently represents a halogen atom; substituted or non-substituted C-C-alkyl; C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted tri(C-C-alkyl)silyl; substituted or non-substituted C-C-alkoxy or C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted C-C-alkylsulfanyl or C-C-halogenoalkylsulfanyl comprising up to 9 halogen atoms that can be the same or different; or wherein two consecutive substituents X together with the phenyl ring form a substituted or non-substituted cyclopentyl or cyclohexyl ring.7. A compound according to wherein X independently represents fluorine claim 1 , chlorine claim 1 , bromine claim 1 , iodine claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , isopropyl claim 1 , butyl claim 1 , isobutyl claim 1 , secbutyl claim 1 , terbutyl claim 1 , cyclopropyl claim 1 , cyclopentyl claim 1 , ...

Подробнее
28-03-2013 дата публикации

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

Номер: US20130079306A1
Принадлежит: Individual

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27 Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

Подробнее
11-04-2013 дата публикации

THIAZOLES, IMIDAZOLES, AND PYRAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES

Номер: US20130090479A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and the compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of the inventions. 128-. (canceled) The present application is a continuation of U.S. patent application Ser. No. 12/538,396, filed Aug. 10, 2009, which is a divisional of U.S. patent application Ser. No. 11/786,464 filed Apr. 11, 2007,now U.S. Pat. No. 7,589,214, and which claims the benefit of U.S. Provisional Application No. 60,791.083, filed Apr. 11, 2006; each of which is incorporated by reference in its entirety.The present invention relates to compounds useful as inhibitors of protein kinases. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. The invention also relates to processes for preparing the compounds of the invention.The search for new therapeutic agents has been greatly aided in recent years by a better understanding of the structure of enzymes and other biomolecules associated with diseases. One important class of enzymes that has been the subject of extensive study is protein kinases.Protein kinases constitute a large family of structurally related enzymes that are responsible for the control of a variety of signal transduction processes within the cell. (See, Hardie, G. and Hanks, S. The Protein Kinase Facts Book, I and II, Academic Press, San Diego, Calif.: 1995). Protein kinases are thought to have evolved from a common ancestral gene due to the conservation of their structure and catalytic function. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The kinases may be categorized into families by the substrates they ...

Подробнее
18-04-2013 дата публикации

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

Номер: US20130096162A1
Принадлежит:

The invention is directed to compounds having the formula: 2. The compound of claim 1 , wherein r is 1.3. (canceled)5. The compound of claim 4 , wherein Ris selected from —COOH claim 4 , —SONHR claim 4 , and tetrazol-5-yl.711-. (canceled)12. The compound of claim 1 , wherein Ris selected from —Calkyl and —Calkylene-O—Calkylene-R claim 1 , where Ris —Calkyl.13. The compound of claim 12 , wherein Ris selected from —Calkyl and —O—Calkyl.14. The compound of claim 1 , wherein X is —Calkylene- claim 1 , 1 to 4-CH-moieties in the alkylene are replaced with a —NR—C(O)— or —C(O)—NR— moiety claim 1 , and Ris selected from H and —OH.15. The compound of wherein X is selected from: —C(O)NH—; —CH—NHC(O)—; —C(O)NH—CH—; —C(O)NH—NHC(O)—; —CH═C(—CH-2-thiophene)-C(O)NH—; —(CH)—NHC(O)—; —C(O)NH—CH—CH(COOH)—CH—; —C(O)NH—CH(benzyl)-CH—NHC(O)—; —C(O)NH—CH(benzyl)-CH—C(O)NH—; —CH—NHC(O)—CH—NHC(O)—; —CH—NHC(O)-cyclohexylene-NHC(O)—; —CH—N(OH)C(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—CH—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—C(O)N(OH)—CH—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; and —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—.16. The compound of claim 15 , wherein X is selected from —C(O)NH— and —CH—NHC(O)—.17. The compound of claim 1 , wherein Ris selected from —Calkylene-SR claim 1 , —Calkylene-C(O)NRR claim 1 , —Calkylene-NR—C(O)R claim 1 , —NH—Calkylene-P(O)(OR) claim 1 , —Calkylene-P(O)ORR claim 1 , —Calkylene-CHR—COOH claim 1 , and —Calkylene-C(O)NR—CHR—COOH; Ris H claim 1 , Ris —OH claim 1 ...

Подробнее
18-04-2013 дата публикации

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

Номер: US20130096301A1
Принадлежит: UNIVERSITY HEALTH NETWORK

The present invention is directed to novel synthetic methods for preparing a spiro cyclopropyl indolinone compound represented by Structural Formula (A): (A) or its pharmaceutically acceptable salt thereof. Also included are synthetic intermediates described herein. 2. (canceled)4. The method of claim 3 , wherein Xand Xare —OSOR″ claim 3 , wherein R″ is Calkyl or phenyl optionally substituted one or more substituents independently selected from the group consisting of halogen claim 3 , nitro claim 3 , Calkyl and Calkoxy;{'sub': '1-6', 'the base is an alkali metal hydride, an alkali metal amide, an alkali metal hydroxide, an alkyl alkali metal, an aryl alkali metal or an alkali metal Calkoxide; and'}the reaction is carried out in an aprotic organic solvent.5. (canceled)6. The method of claim 4 , wherein the base is an alkali metal hydride; and the aprotic organic solvent is selected from tetrahydrofuran claim 4 , diethylether claim 4 , dimethoxyethane claim 4 , toluene claim 4 , methylene chloride claim 4 , dimethyl formamide claim 4 , dimethyl sulfoxide claim 4 , acetonitrile claim 4 , dioxane claim 4 , methyl tert-butyl ether claim 4 , 1 claim 4 ,2-dichloroethane claim 4 , or a combination thereof.710-. (canceled)11. The method of claim 6 , wherein:{'sup': 1', 'P', 'P, 'sub': 2', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6, 'Pis —C(═O)O—R, —SO—R, tetrahydro-2H-pyran-2-yl or benzyl optionally substituted one or more substituents independently selected from the group consisting of halogen, nitro, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy and (Calkoxy)Calkyl;'}{'sup': 2', 'P', 'P, 'sub': 1-6', '1-6', '1-6', '1-6', '2', '1-6', '1-6', '1-6', '1-6', '1-6', '1-6, 'Pis Calkyl, Chaloalkyl, (Calkoxy)Calkyl, —C(═O)O—R, —SO—R, tetrahydro-2H-pyran-2-yl or benzyl optionally substituted one or more substituents independently selected from the group consisting of halogen, nitro, Calkyl, Chaloalkyl, Calkoxy, Chaloalkoxy, (Calkoxy)Calkyl; and'}{'sup': 'P', 'sub': 1-6', '1-6', '1-6', '1-6 ...

Подробнее
25-04-2013 дата публикации

Compounds, Compositions, And Methods For Reducing Or Eliminating Bitter Taste

Номер: US20130101684A1
Принадлежит: CHROMOCELL CORPORATION

The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product. 710.-. (canceled)1355.-. (canceled)5661112. The composition of any one of - claims 1 , or claims 1 , further comprising a bitter tastant.576111256. The composition of any one of - claims 1 , claims 1 , or claims 1 , wherein the composition further comprises one or more components selected from the group consisting of: NaCl claims 1 , sodium lactate and sugar.58611125657. The composition of any one of - claims 1 , claims 1 , claims 1 , or claims 1 , wherein the composition is found in a food product or a consumer product.5961112. The composition of any one of - claims 1 , or claims 1 , wherein the composition further comprises a pharmaceutically active ingredient claims 1 , and optionally claims 1 , a bitter tastant.60. The composition of claim 59 , wherein the pharmaceutically active ingredient is bitter.61. The composition of or claim 59 , wherein the pharmaceutically active ingredient or bitter tastant is a potassium salt.62. The composition of any one of claim 59 , or claim 59 , wherein the bitter tastant is a potassium salt claim 59 , and wherein the potassium salt is potassium chloride or potassium lactate.6361112. A method of use of the composition of any one of - claims 1 , or claims 1 , wherein the method comprises:(a) providing a comestibly acceptable carrier; and{'claim-ref': {'@idref': 'CLM-00001', 'claims 1'}, 'b': '8', '(b) adding to the comestibly acceptable carrier, a composition as described in any of - or combinations thereof.'}64. The method of claim 63 , wherein the method further comprises adding a bitter tastant to the comestibly acceptable carrier.65. The ...

Подробнее
25-04-2013 дата публикации

PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS

Номер: US20130102610A1
Принадлежит: HIGH POINT PHARMACEUTICALS, LLC

Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPARδ and should be useful for treating conditions mediated by the same. 1. A compound selected from the group consisting of:(Z)-[2-Methyl-4-[3-(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid;(E)-[2-Methyl-4-[3-[4-[3-(pyrazol-1-yl)prop-1-ynyl]phenyl]-3-(4-trifluoromethylphenyl)allyloxy]phenoxy]acetic acid;(E)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl) allyloxy]-phenoxy]acetic acid;(E)-[2-Methyl-4-[3(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid; and(Z)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl) allyloxy]-phenoxy]acetic acid;or a pharmaceutically acceptable salt thereof.2. The compound of claim 1 , wherein the compound is (Z)-[2-Methyl-4-[3(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.3. A compound selected from the group consisting of: (E)-[2-Methyl-4-[3-[4-[3-(pyrazol-1-yl)prop-1-ynyl]phenyl]-3-(4-trifluoromethylphenyl)-allyloxy]phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.4. The compound of claim 3 , wherein the compound is (E)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl)allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.5. A compound selected from the group consisting of: (E)-[2-Methyl-4-[3-(4-methylphenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.6. The compound of claim 1 , wherein the compound is (Z)-[2-Methyl-4-[3-[4-[3-(morpholin-4-yl)propynyl]phenyl]-3-(4-trifluoromethylphenyl)allyloxy]-phenoxy]acetic ...

Подробнее
25-04-2013 дата публикации

METHOD OF TREATING DIABETES, METABOLIC SYNDROME AND OBESITY USING PHENYLACETAMIDE DERIVATIVE

Номер: US20130102617A1
Принадлежит: Astellas Pharma Inc.

Phenylacetamide compounds of the formula 1. (canceled)2. The method of claim 18 , wherein n is 0.3. The method of claim 2 , wherein Ris methyl claim 2 , trifluoromethyl claim 2 , or cyclopropyl.4. The method of claim 3 , wherein Ris cyclopropyl.6. The method of claim 5 , wherein Ring A is pyrazolyl claim 5 , thiazolyl claim 5 , thiadiazolyl claim 5 , pyridyl or pyrazinyl claim 5 , each of which may be substituted with up to five moieties independently selected from the group consisting of halogen claim 5 , cyano claim 5 , lower alkyl which may be substituted with —OR claim 5 , —OR claim 5 , —O-lower alkylene —OR claim 5 , and —C(O)R.7. The method of claim 6 , wherein [Chem. 21] is a single bond.8. The method of claim 6 , wherein [Chem. 22] is a double bond.9. The method of claim 18 , wherein the compound is selected from the group consisting of:(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyrazin-2-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(1-methyl-1H-pyrazol-3-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2E)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-fluoro-1,3-thiazol-2-yl)-3-[(1S)-3-oxocyclopentyl]acrylamide,(2R)—N-(4-acetyl-1,3-thiazol-2-yl)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyridin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methylpyrazin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-[5-(hydroxymethyl)pyrazin-2-yl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)—N-(5-chloropyrazin-2-yl)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-N-(5-methoxypyrazin-2-yl)-3-[(1R)-3-oxocyclopentyl]propanamide,(2R)-2-[3-cyclopropyl-4-(cyclopropylsulfonyl)phenyl]-3-[(1R)-3-hydroxycyclopentyl]-N-(5 ...

Подробнее
25-04-2013 дата публикации

FUNGICIDE N-CYCLOALKYL-N-BICYCLIMETHYLENE-CARBOXAMIDE DERIVATIVES

Номер: US20130102790A1
Принадлежит:

The present invention relates to N-cycloalkyl-N-bicyclicmethylene-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group, T represents O or S, Zrepresents a C-C-cycloalkyl group, X represents N or a CZand Y, Y, Z, Z, Land Lrepresent various substituents. Their process of preparation, the preparation of intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions are also disclosed. 118-. (canceled)20. The compound of wherein Yis C-C-alkyl and Yis hydrogen.21. The compound of wherein Yis methyl.22. The compound of wherein Yand Yare both C-C-alkyl.23. The compound of wherein Yand Yare both methyl.24. The compound of wherein Zis hydrogen.25. The compound of wherein Lis CZZ.26. The compound of wherein Lis CZZand m is 1 or 2.27. The compound of wherein Zand each Zare independently selected from the group consisting of a hydrogen atom claim 19 , a halogen atom claim 19 , C-C-alkyl claim 19 , C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different claim 19 , C-C-alkoxy claim 19 , and C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different.28. The compound of wherein said compound is N-cyclopropyl-3-(difluoromethyl)-N-[1-(1-hydroxy-1 claim 19 ,2 claim 19 ,3 claim 19 ,4-tetrahydronaphthalen-1-yl)ethyl]-1-methyl-1H-pyrazole-4-carboxamide. The present invention relates to N-cycloalkyl-N-bicyclicmethylene-carboxamide or thiocarboxamide derivatives, their process of preparation, preparation of intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.In international patent application WO2007060164 ...

Подробнее
02-05-2013 дата публикации

C7-Fluoro Substituted Tetracycline Compounds

Номер: US20130109657A1
Принадлежит: Tetraphase Pharmaceuticals Inc

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Подробнее
02-05-2013 дата публикации

SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY

Номер: US20130109692A1
Принадлежит: LABORATORIOS DEL DR. ESTEVE, S.A.

The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs. 119-. (canceled)20. A method for treating a patient afflicted with or at risk of emesis induced by chemotherapy or by radiotherapy comprising administering to the patient a sigma ligand in an amount effective to treat the patient.22. The method of claim 21 , wherein in the compound Ris H claim 21 , —CORor substituted or unsubstituted alkyl.23. The method of claim 21 , wherein in the compound Ris H or alkyl.24. The method of claim 21 , wherein in the compound Rand Rtogether form a fused naphthyl ring system.25. The method of claim 21 , wherein in the compound wherein Rand Rtogether form a morpholine-4-yl group.26. The method of claim 21 , wherein the sigma ligand is selected from the group consisting of:4-{2-(1-(3,4-dichlorophenyl)-5-methyl-1H pyrazol-3-yloxy)ethyl}morpholine,2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]-N,N-diethylethanamine,1-(3,4-Dichlorophenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole,1-(3,4-Dichlorophenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]-1H-pyrazole,1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperidine,1-{2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-1H-imidazole,3-{1-[2-(1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl]piperidin-4-yl}-3H-imidazo[4,5-b]pyridine,1-{2-[1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}-4-methylpiperazine,Ethyl 4-{2-[1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}piperazine carboxylate,1-(4-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yloxy)ethyl)piperazin-1-yl)ethanone,4-{2-[1-(4-Methoxyphenyl)-5-methyl-1H-pyrazol-3-yloxy]ethyl}morpholine,1-(4-Methoxyphenyl)-5-methyl-3-[2-(pyrrolidin-1-yl)ethoxy]-1H-pyrazole,1-(4-Methoxyphenyl)-5-methyl-3-[3-(pyrrolidin-1-yl)propoxy]- ...

Подробнее
02-05-2013 дата публикации

Chemical Compounds

Номер: US20130109701A1
Принадлежит: PFIZER LIMITED

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfon-amide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar, R, R, R, Rand Rare as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain. 2. A compound according to wherein X is —OCH—.3. A compound according to wherein X is —CHO—.4. A compound according to wherein Aris phenyl independently substituted by one to three Y.5. A compound according to wherein Arphenyl independently substituted by one or two Y.6. A compound according to wherein Aris phenyl meta-substituted by Y claim 1 , para-substituted by Y claim 1 , or meta- and para-substituted by independent Y.7. A compound according to wherein Y is F; Cl; CN; (C-C)alkyl claim 1 , optionally substituted by (C-C)cycloalkyl or one to three F; (C-C)cycloalkyl claim 1 , optionally substituted by one to three F; (C-C)alkyloxy claim 1 , optionally substituted by one to three F; or (C-C)cycloalkyloxy.8. A compound according to wherein Ris (C-C)alkyl or (C-C)cycloalkyl.9. A compound according to wherein Ris (C-C)alkyl or (C-C)cycloalkyl.10. A compound according to wherein R claim 1 , Rand Rare independently H claim 1 , F or Cl.11. A compound according to wherein Ris H; CN; F; Cl; (C-C)alkyl claim 1 , optionally substituted by one to three F; or (C-C)alkyloxy claim 1 , optionally substituted by one to three F.12. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof together claim 1 , as defined in claim 1 , with one or more pharmaceutically acceptable excipients.13. A pharmaceutical composition according to including one or more additional therapeutic agents.14. (canceled)15. (canceled)16. (canceled)17. ( ...

Подробнее
02-05-2013 дата публикации

HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS

Номер: US20130109863A1
Принадлежит: Janssen Pharmaceutica N.V.

Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever. 123-. (canceled)251. A compound of claim wherein Rand Rtaken together form an optionally substituted imidazole and enantiomers , diastereomers , tautomers , or pharmaceutically acceptable salts thereof.26. A compound selected from the group consisting of:pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide;5-Methyl-1H-pyrazole-3-carboxylic acid (4-hydroxy-phenyl)-amide; and3H-Imidazole-4-carboxylic acid (4-hydroxy-phenyl)-amide;and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.27. A compound of claim 26 , wherein the compound is pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide and enantiomers claim 26 , diastereomers claim 26 , tautomers claim 26 , or pharmaceutically acceptable salts thereof.28. A compound of claim 26 , wherein the compound is 5-Methyl-1H-pyrazole-3-carboxylic acid (4-hydroxy-phenyl)-amide and enantiomers claim 26 , diastereomers claim 26 , tautomers claim 26 , or pharmaceutically acceptable salts thereof.30. A composition of claim 29 , wherein Rand Rtaken together form an optionally substituted imidazole and enantiomers claim 29 , diastereomers claim 29 , tautomers claim 29 , or pharmaceutically acceptable salts thereof.31. A composition comprising a compound selected from the group consisting of:pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide;5-Methyl-1H-pyrazole-3-carboxylic acid (4-hydroxy-phenyl)-amide; and3H-Imidazole-4-carboxylic acid (4-hydroxy-phenyl)-amide;and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.32. The composition of wherein the compound is pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide and enantiomers claim 31 , diastereomers claim 31 , tautomers claim 31 , or pharmaceutically acceptable salts thereof.33. The composition of ...

Подробнее
09-05-2013 дата публикации

PYRAZOLE COMPOUND

Номер: US20130116296A1
Принадлежит:

The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HTantagonistic action (antidepressive and anxiolytic effects), in particular, 5-HTinverse agonistic action comprising Compound (1): 2. The compound of or a pharmaceutically acceptable salt thereof wherein{'sup': 1', '2', '3, 'R, Rand Rare independently selected from the group consisting of hydrogen atom and methyl group, and'}{'sup': '4', 'Ris hydrogen atom.'}3. The compound of or a pharmaceutically acceptable salt thereof wherein A is an optionally-substituted Caryl group.4. The compound of or a pharmaceutically acceptable salt thereof wherein X is hydrogen atom.5. The compound of or a pharmaceutically acceptable salt thereof wherein L is oxygen atom.6. The compound of or a pharmaceutically acceptable salt thereof wherein n is 1.7. The compound of or a pharmaceutically acceptable salt thereof wherein{'sup': 1', '3', '4, 'R, Rand Rare hydrogen atom, and'}{'sup': '2', 'Ris methyl group.'}8. The compound of or a pharmaceutically acceptable salt thereof wherein R claim 1 , R claim 1 , Rand Rare hydrogen atom.9. The compound of or a pharmaceutically acceptable salt thereof wherein E is an optionally-substituted Ccycloalkyl group claim 1 , an optionally-substituted 5- to 10-membered saturated heterocyclic group which comprises 1 to 3 oxygen atoms as a constituent atom of the ring claim 1 , or an optionally-substituted phenyl group.10. The compound of or a pharmaceutically acceptable salt thereof wherein E is an optionally-substituted Ccycloalkyl group.11. The compound of or a pharmaceutically acceptable salt thereof wherein r is 1 or 2.12. The compound of or a pharmaceutically acceptable salt thereof wherein Ris an optionally-substituted Calkyl group.13. The compound of wherein the compound of Formula (1) is any one of the following compounds claim 1 , or a pharmaceutically acceptable salt thereof:1-[5-(benzyloxy)-1-(cyclohexylmethyl)-1H-pyrazol-3-yl]-N-methylmethanamine;1-{1-( ...

Подробнее
16-05-2013 дата публикации

COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM

Номер: US20130123265A1
Принадлежит: CalciMedica, Inc.

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC channel activity. 2. The compound of claim 1 , wherein:{'sup': '1', 'Ris hydrogen, methyl, ethyl, n-propyl or iso-propyl.'}3. The compound of or claim 1 , wherein:{'sup': 4', '8, 'sub': 2', '3', '3', '1', '6', '1', '6', '1', '6', '3', '8', '1', '6, 'Ris a phenyl, optionally substituted with at least one substituent selected from F, Cl, Br, I, —CN, —NO, —CF, —OH, —OR, —OCF, C-Calkyl, C-C-fluoroalkyl, C-Cheteroalkyl, C-Ccycloalkyl, and C-Chaloalkyl.'}54. The compound of any of claim 1 , claim 1 , or claim 1 , wherein:{'sup': 4', '8', '9', '9', '9', '9', '9', '8', '9', '9', '9', '8', '9', '8', '9', '9', '8', '8, 'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris substituted with at least one substituent selected from —NHS(═O)R, —S(═O)N(R), —N(R)S(═O)N(R), —N(R), —N(R)C(═O)R, —N(R)C(═O)N(R), —N(R)C(═O)OR, —COR, —C(═O)R, —OC(═O)N(R), —CON(R), —SR, or —S(═O)R.'}6. The compound of claim 1 , wherein:{'sup': '4', 'Ris selected from phenyl; 2-fluorophenyl; 3-fluorophenyl; 4-fluorophenyl; 2-chlorophenyl; 3-chlorophenyl; 4-chlorophenyl; 2,4-dichlorophenyl; 2,3-dichlorophenyl; 3,4-dichlorophenyl; 3,5-dichlorophenyl; 2-bromophenyl; 3-bromophenyl; 4-bromophenyl; 2-iodophenyl; 3-iodophenyl; 4-iodophenyl; 2-methylphenyl; 3-methylphenyl; 4-methylphenyl; 2,4-dimethylphenyl; 2,3-dimethylphenyl; 3,4-dimethylphenyl; 3,5-dimethylphenyl; 2-trifluoromethylphenyl; 3-trifluoromethylphenyl;'}{'b': '4', 'and -trifluoromethylphenyl.'}76. The compound of - claims 1 , wherein:{'sup': 2', '8, 'sub': 2', '3', '3', '1', '6', '1', '6', '1', '6', '3', '8', '1', '6, 'Ris a phenyl, optionally substituted with at least one ...

Подробнее
16-05-2013 дата публикации

LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT

Номер: US20130123296A1
Принадлежит: The University of Kansas

Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject. 124.-. (canceled)26. A method as in claim 25 , wherein{'sub': '1', 'wherein Ris carboxyl, acryl, or carboxylic acid hydrazide; and'}{'sub': '2', 'wherein Ris halogen, alcohol, alkoxy, aralkyl, cycloalkyl, haloalkyl, haloalkoxy, amino, or carboxyl.'}27. A method as in claim 25 , wherein{'sub': '1', 'Rincludes one or more of a carboxylic acid, carboxylic acid ester, propionic acid, 2-methyl propionic acid, oxirane-carboxylic acid, cyclopropane carboxylic acid, propionic acid methyl ester, 2-methyl propionic acid methyl ester, oxirane-carboxylic acid methyl ester, or cyclopropane carboxylic acid methyl ester; and/or'}{'sub': '2', 'Rincludes a halogen, haloalkyl, or haloalkoxy.'}28. A method as in claim 25 , wherein the claim 25 , compound is selected from the group consisting of:3-[1-(2,4-dichlorobenzyl)-6-trifluoromethyl-1H-indazol-3-yl]-acrylic acid;6-chloro-1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid hydrazide;1-(2,4-dichlorobenzyl)-6-fluoro-1H-indazole-3-carboxylic acid methyl ester;6-fluoro-1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid hydrazide;3-[1-(2,4-dichlorobenzyl)-6-fluoro-1H-indazol-3-yl]-acrylic acid;3-[1-(2,4-dichlorobenzyl)-6-chloro-1H-indazol-3-yl]-acrylic ...

Подробнее
16-05-2013 дата публикации

BENZOCYCLOALKENES AS ANTIFUNGAL AGENTS

Номер: US20130123322A1
Принадлежит:

The present invention relates to fungicidal benzocycloalkene carboxamides or their thiocarboxamide derivatives of formula (I), their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. 3. A compound of formula (I) according to wherein A is selected in the list consisting of A; A; Aand A.4. A compound of formula (I) according to wherein A represents Awherein Rrepresents a substituted or non-substituted C-C-alkyl claim 2 , C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different;{'sub': 1', '5', '1', '5, 'sup': 35', '36, 'or a substituted or non-substituted C-C-alkoxy; Rrepresents a hydrogen atom or a halogen atom and Rrepresents a substituted or non-substituted C-C-alkyl.'}5. A compound of formula (I) according to wherein T represents O.6. A compound of formula (I) according to wherein Lor Lindependently represents O or CZZ.7. A compound of formula (I) according to wherein Lor Lindependently represents a direct bond claim 1 , O or CZZ.8. A compound of formula (I) according to wherein X independently represents a halogen atom; substituted or non-substituted C-C-alkyl; C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted tri(C-C-alkyl)silyl; substituted or non-substituted C-C-alkoxy or C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different; or wherein two consecutive substituents X together with the phenyl ring form a substituted or non substituted 1 claim 1 ,3-benzodioxolyl; 1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydro-quinoxalinyl; 3 claim 1 ,4-dihydro-2H-1 claim 1 ,4-benzoxazinyl; 1 claim 1 ,4-benzodioxanyl; indanyl; 2 claim 1 ,3-dihydrobenzofuranyl; or indolinyl.9. A compound of formula (I) according to wherein Z claim 1 , Z claim 1 , Z ...

Подробнее
16-05-2013 дата публикации

FUNGICIDAL PYRAZOLES

Номер: US20130123323A1
Принадлежит: E I DU PONT DE NEMOURS AND COMPANY

Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, 2. A compound of wherein{'sup': 1', '5', '5', '5, 'Qis phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, each substituted with from 1 to 4 substituents independently selected from R; provided that when an Rsubstituent is located at a meta position, then said Rsubstituent is selected from F, Cl, Br and cyano;'}{'sup': 2', '5', '5', '5, 'Qis phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, each substituted with 1, 2 or 3 substituents independently selected from R, provided that when an Rsubstituent is located at a meta position, then said Rsubstituent is selected from F, Cl, Br and cyano;'}{'sup': '2', 'sub': 1', '2, 'Ris C-Calkyl, Cl or Br; and'}{'sup': '5', 'sub': 1', '4', '1', '4', '1', '3', '1', '3', '1', '3', '1', '3', '1', '3', '1', '3', '1', '3', '1', '3', '3', '4', '2, 'each Ris independently selected from halogen, cyano, nitro, amino, methylamino, dimethylamino, C-Calkyl, C-Chaloalkyl, C-Calkoxy, C-Chaloalkoxy, C-Calkylthio, C-Chaloalkylthio, C-Calkylsulfinyl, C-Chaloalkylsulfinyl, C-Calkylsulfonyl, C-Chaloalkylsulfonyl, C-Ccycloalkyl, C(═S)NHand -U-V-T.'}3. A compound of wherein:{'sup': 1', '5, 'Qis phenyl or pyridinyl, each substituted with 1, 2 or 3 substituents independently selected from R;'}{'sup': 2', '5, 'Qis phenyl or pyridinyl, each substituted with 1, 2 or 3 substituents independently selected from R;'}{'sup': '2', 'sub': '3', 'Ris CH, Cl or Br;'}{'sup': '3', 'sub': '3', 'Ris H, F, Cl, Br or CH;'}{'sup': '4', 'Ris F, Cl or Br;'}{'sup': '5', 'sub': 1', '4', '1', '4', '1', '3', '1', '3, 'each Ris independently selected from halogen, cyano, nitro, C-Calkyl, C-Chaloalkyl, C-Calkoxy, C-Chaloalkoxy and -U-V-T;'}each U is independently O or NH;{'sub': 2', '4, 'each V is C-Calkylene;'}{'sup': 10a', '10b', '11, 'each T is independently NRRor OR;'}{'sup': 10a', '10b, 'sub': 1', '6', '1', '6, 'each Rand Ris independently H, C-Calkyl ...

Подробнее
16-05-2013 дата публикации

Ethinyl-pyrazole derivative

Номер: US20130123500A1
Принадлежит: Taisho Pharmaceutical Co Ltd

Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.

Подробнее
16-05-2013 дата публикации

BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Номер: US20130123507A1
Принадлежит:

The bicyclo-substituted pyrazolon-azo derivatives of formula (I) or pharmaceutical acceptable salts, hydrates or solvates thereof, methods for their preparation, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor are disclosed. The definition of substituents in formula (I) are the same as defined in the description. 113-. (canceled)15. The compound according to claim 14 , wherein R claim 14 , R claim 14 , and Rare hydrogen.16. The compound according to claim 14 , wherein R claim 14 , R claim 14 , R claim 14 , and Rare each independently hydrogen claim 14 , methyl claim 14 , and ethyl. This disclosure relates to novel bicyclo-substituted pyrazolon-azo derivatives represented by formula (I), methods for their preparation, pharmaceutical compositions containing the same, and their use as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics and their use as agonists of the thrombopoietin receptor.Thrombopoietin (TPO), also called megakaryocyte growth and development factor (MGDF), thrombocytopoiesis stimulating factor (TSF), c-myeloproliferative leukemia ligand (c-Mpl), mpl ligand, or megapoietin, is a glycoprotein that has been shown to be involved in the production of platelets. See Wendling, F., et. al., Biotherapy 10(4): 269-77 (1998); Kuter D. I. et al., The Oncologist, 1: 98-106 (1996); Metcalf, Nature 369: 519-520 (1994).Under certain circumstances, the activity of TPO results from the binding of TPO with the TPO receptor (also called MPL). The TPO receptor has been cloned and its amino acid sequence has been described. See Vigon et al., Proc. Nat. Acad. Sci., 89: 5640-5644 (1992).TPO is a 332-amino acid glycosylated polypeptide that plays a key role in the regulation of megakaryocytopoiesis, and in the process in which platelets are produced by bone marrow megakaryocytes. See Kuter et al., Proc. Natl. Acad. Sci. USA 91 ...

Подробнее
16-05-2013 дата публикации

Process for the preparation of esters of 1-substituted-3-fluoroalkyl-pyrazole-4-carboxylic acids

Номер: US20130123510A1
Принадлежит: SOLVAY SA

A process for the manufacture of an ester or the respective free acid of a 1-substituted-3-fluoroalkyl-pyrazole-4-carboxylic acid of formula (I), wherein in such formula (I), Y is H, F or an alkyl group having from 1 to 12 carbon atoms which is optionally substituted by at least one halogen atom, an aralkyl group or an aryl group; Ris H or an organic residue; Ris H or an organic residue. Such process comprises submitting a compound of formula (II) to a reduction reaction, wherein in such formula (II), Y is the same as defined for formula (I); X is Cl, Br or I; R′ is H or an organic residue; and R′ is H or an organic residue. 2. The process according to claim 1 , wherein Ris methyl claim 1 , ethyl claim 1 , n-propyl or isopropyl.3. The process according to claim 1 , wherein Ris methyl.4. The process according to claim 1 , wherein X is Cl; and wherein Y is F.5. The process according to claim 1 , wherein the reduction is carried out with hydrogen in the presence of a hydrogenation catalyst selected from the group consisting of metals from Group VIII of the Periodic Table of the Elements.6. The process according to claim 5 , wherein the catalyst is a supported catalyst with a support selected from the group consisting of alumina claim 5 , silica claim 5 , and carbon.7. The process according to claim 1 , wherein the temperature of the reaction is from −10° C.8. The process according to claim 1 , wherein the pressure of the reaction is from 1 bar absolute to 30 bar absolute; and wherein the molar ratio of hydrogen to a compound of formula (II) is from 1 to 1000.9. The process according to claim 1 , wherein the reduction reaction is conducted in the presence of at least one additive selected from the group consisting of KCO claim 1 , NHCl claim 1 , NHF claim 1 , CsF claim 1 , and Borax.11. The method according to claim 10 , wherein X is Cl; and wherein Y is F.12. The method according to claim 10 , wherein the reaction in step (b) is carried out in a hydrofluorocarbon ...

Подробнее
23-05-2013 дата публикации

FUNGICIDAL PYRAZOLES AND THEIR MIXTURES

Номер: US20130129839A1
Принадлежит: E I DU PONT DE NEMOURS AND COMPANY

Disclosed is a fungicidal composition comprising (a) at least one compound selected from the compounds of Formula 1, N-oxides, and salts thereof, 2. The composition of wherein component (a) comprises a compound of Formula 1 or salt thereof claim 1 , wherein in Formula 1 claim 1 ,{'sup': 2', '3, 'at most, only one of Rand Ris H; and'}{'sup': 5', '6, 'at most, only one of Rand Ris H.'}3. The composition of wherein in Formula 1 claim 2 ,{'sup': '1', 'Ris F, Cl or Br;'}{'sup': '2', 'Ris H, cyano, F, Cl, Br or methoxy;'}{'sup': '3', 'Ris H, F or Cl;'}{'sup': '4', 'Ris F, Cl or Br;'}{'sup': '5', 'Ris H, cyano, F, Cl or methoxy; and'}{'sup': '6', 'Ris H or F.'}4. The composition of wherein in Formula 1 claim 3 ,{'sup': '3', 'Ris H or F; and'}{'sup': '5', 'Ris cyano, F, Cl or methoxy.'}5. The composition of wherein component (a) comprises a compound selected from the group consisting ofN,4-bis(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine,N-(2-bromo-4,6-difluorophenyl)-4-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine,N-(2-bromo-4,6-difluorophenyl)-4-(2-bromo-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine,N-(2-bromo-4,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine,N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-5-amine,4-[5-[(4-chloro-2-fluorophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-3,5-difluorobenzonitrile,N-(2-chloro-4,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine,4-[5-[(2-chloro-4,6-difluorophenyl)amino]-1,3-dimethyl-1H-pyrazol-4-yl]-3-fluorobenzonitrile,4-[[4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-yl]oxy]-3,5-difluorobenzonitrile,4-(2-chloro-4-fluorophenyl)-N-(2,4-dichloro-6-fluorophenyl)-1,3-dimethyl-1H-pyrazol-5-amine,4-(2-chloro-4-fluorophenyl)-N-(2,6-difluoro-4-methoxyphenyl)-1,3-dimethyl-1H-pyrazol-5-amine,4-(2-chloro-4-fluorophenyl)-α-(2,4-difluorophenyl)-1,3-dimethyl-1H-pyrazole-5-methanol,N-(2,4-dichloro-6-fluorophenyl)-4-(2,4- ...

Подробнее
23-05-2013 дата публикации

N-[(HET)ARYLETHYL)] PYRAZOLE(THIO)CARBOXAMIDES AND THEIR HETEROSUBSTITUTED ANALOGUES

Номер: US20130131119A1
Принадлежит:

The present invention relates to fungicidal N-[(het)arylethyl)] pyrazolecarboxamide or thiocarboxamide and their heterosubstituted analogues, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. 2. A compound according to wherein Xand Xindependently represent a chlorine or a fluorine atom.3. A compound according to wherein Y represents methyl.4. A compound according to wherein T represents O.5. A compound according to wherein B represents a substituted or non-substituted phenyl ring; a substituted or non-substituted naphthyl ring; a substituted or non-substituted pyridyl ring; a substituted or non-substituted thienyl ring; or a substituted or non-substituted benzothienyl ring; preferably a substituted or non-substituted phenyl ring or a substituted or non-substituted 2-pyridyl ring.6. A compound according to wherein X independently represents a halogen atom; substituted or non-substituted C-C-alkyl; C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted tri(C-C-alkyl)silyl; substituted or non-substituted C-C-alkoxy or C-C-halogenoalkoxy comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted C-C-alkylsulfanyl or C-C-halogenoalkylsulfanyl comprising up to 9 halogen atoms that can be the same or different; or wherein two consecutive substituents X together with the phenyl ring form a substituted or non-substituted cyclopentyl or cyclohexyl ring.7. A compound according to wherein X independently represents fluorine claim 1 , chlorine claim 1 , bromine claim 1 , iodine claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , isopropyl claim 1 , butyl claim 1 , isobutyl claim 1 , secbutyl claim 1 , terbutyl claim 1 , cyclopropyl claim 1 , cyclopentyl claim 1 ...

Подробнее
23-05-2013 дата публикации

O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES AND THEIR USE AS FUNGICIDES

Номер: US20130131124A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to O-CYCLOPROPYLCYCLOHEXYL-CARBOXANILIDES derivatives of formula (I); their process of preparation, their use as fungicide, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions. 2. A compound of formula (I) as claimed in claim 1 , wherein{'sup': 1', '2, 'Rand Rare, independently, hydrogen or fluoro;'}{'sup': '3', 'sub': 2-6', '3-8, 'Ris Calkyl, optionally substituted Ccycloalkyl, phenyl, thienyl or furyl;'}A represents one of the radicals A1, A2, A3, A4, A5, A6, A9, A10, A11, A12 or A17;{'sup': '18', 'sub': 1', '2', '1', '2, 'Rrepresents hydrogen, cyano, fluorine, chlorine, bromine, iodine, methyl, ethyl, isopropyl, methoxy, ethoxy, methylthio, ethylthio, cyclopropyl, C-Chaloalkyl C-C-haloalkoxy having in each case 1 to 5 fluorine, chlorine and/or bromine atoms, trifluoromethylthio, difluoromethylthio, aminocarbonyl, aminocarbonylmethyl or aminocarbonylethyl;'}{'sup': '19', 'Rrepresents hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, methoxy, ethoxy, methylthio or ethylthio;'}{'sup': '20', 'sub': 1', '2, 'Rrepresents hydrogen, methyl, ethyl, n-propyl, isopropyl, C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms, hydroxymethyl, hydroxyethyl, cyclopropyl, cyclopentyl, cyclohexyl or phenyl.'}{'sup': 21', '22, 'sub': 1', '2, 'Rand Rindependently of one another represent hydrogen, fluorine, chlorine, bromine, methyl, ethyl or C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup': '23', 'sub': 1', '2', '1', '2, 'Rrepresents fluorine, chlorine, bromine, cyano, methyl, ethyl, C-C-haloalkyl or C-C-haloalkoxy having in each case 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup': 24', '25, 'sub': 1', '2, 'Rand Rindependently of one another represent hydrogen, fluorine, chlorine, bromine, methyl, ethyl or C-C-haloalkyl having 1 to 5 fluorine, chlorine and/or bromine atoms;'}{'sup ...

Подробнее
23-05-2013 дата публикации

Phenylpropionic acid derivative and use thereof

Номер: US20130131134A1
Принадлежит: Individual

A compound represented by the following general formula (1) or a salt thereof, which has superior inhibitory activity against type 4 PLA 2 , and thus has prostaglandin and/or leucotriene production suppressing action [X represents a halogen atom, an alkyl group which may be substituted, or the like, Y represents hydrogen atom or an alkyl group which may be substituted, and Z represents hydrogen atom or an alkyl group which may be substituted].

Подробнее
23-05-2013 дата публикации

COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

Номер: US20130131135A1
Принадлежит: ALLERGAN, INC.

The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula 2. The compound of wherein Ris selected from the group consisting of OH and NHSOCF.3. The compound of wherein Rand Rare H.4. The compound of wherein Ris alkyl.5. The compound of wherein Ris methyl.6. The compound of wherein Ris selected from the group consisting of H claim 2 , hydroxy claim 2 , alkyl claim 2 , aryl claim 2 , alkoxy claim 2 , aryloxy claim 2 , halogen claim 2 , nitro claim 2 , amino claim 2 , cyano and hydroxy claim 2 , halogen claim 2 , nitro claim 2 , amino and cyano-substituted alkyl claim 2 , aryl claim 2 , alkoxy claim 2 , aryloxy and Ris H.7. The compound of wherein Ris selected from the group consisting of H claim 6 , alkyl claim 6 , alkoxy claim 6 , halogen and fluorinated alkyl and alkoxy.8. The compound of wherein Ris selected from the group consisting of chloro claim 7 , bromo and trifluoromethyl.9. The compound of wherein Z is (CH).10. The compound of wherein Y is O.11. The compound of wherein W is selected from the group consisting of alkyl claim 2 , benzylyl and halogen-substituted benzyl.12. The compound of wherein W is selected from the group consisting of alkyls having from 4 to 7 carbon atoms.13. The compound of wherein W is cyclopentyl.14. The compound of claim 11 , wherein said compound is selected from the group consisting of N-(3-{1-[5-Chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yl}-propionyl)-C claim 11 ,C claim 11 ,C-trifluoromethanesulfonamide claim 11 ,3-{1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-5-methyl- ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
23-05-2013 дата публикации

Process for Preparing 1-phenylpyrazoles

Номер: US20130131352A1
Принадлежит: BASF SE

The present invention to a process for preparing 1-phenylpyrazoles of the formula I 2. The compound of claim 1 , wherein m is 0.3. The compound of claim 1 , wherein p is 0 or 1.4. The compound of claim 1 , wherein p is 1 and Ris located meta or para to the attachment point of the methylene bridge.5. The compound of claim 1 , wherein Ris chlorine claim 1 , fluorine claim 1 , C-C-alkyl or C-C-haloalkyl.6. The compound of claim 1 , wherein Ris methoxy claim 1 , halomethoxy or benzyloxy.7. The compound of claim 1 , wherein Ris methyl or halomethyl.8. The compound of claim 1 , wherein Y is nitro or a group R.9. The compound of claim 1 , wherein Y is nitro or a group Rand wherein m is 0 and p is 0. This application is a continuation of U.S. application Ser. No. 13/393,624, filed Mar. 1, 2012, which application is a national stage application of International Application No. PCT/EP2010/062950, filed Sep. 3, 2010, the entire contents of which is hereby incorporated herein by reference. This application also claims priority under 35 U.S.C. §119 to European Patent Application No. 09169528.8 filed Sep. 4, 2009, the entire contents of which is hereby incorporated herein by reference.The present invention relates to a process for preparing 1-phenylpyrazoles. In particular, the invention relates to a process for preparing 1-phenylpyrazoles by C—N coupling of a phenyl halide and a pyrazole compound.1-Phenylpyrazols are of great interest especially as pharmaceutical and pesticide pharmacophors, and as precursors of such active ingredients. Pyraclostrobine is a prominent representative of a pesticidal N-phenylpyrazole derivative.The most important method for preparing this class of heterocycles involves the double condensation of 1,3-diketones with phenyl hydrazine or its derivatives. This method has a wide scope not only because of the readily availability of 1,3-diketones but also because one carbonyl of the diketone starting material can be replaced by an acetal, a hemiacetal, a ...

Подробнее
30-05-2013 дата публикации

HETEROARYL (ALKYL) DITHIOCARBAMATE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Номер: US20130136794A1
Принадлежит: PEKING UNIVERSITY

Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer. 2. The compound according to claim 1 , wherein the group A is substituted or unsubstituted heterocyclic group claim 1 , is the heterocyclic group being selected from pyridyl claim 1 , pyrimidinyl claim 1 , pyrazinyl claim 1 , furyl claim 1 , oxazolyl claim 1 , pyrazolyl claim 1 , thiazolyl or oxadiazolyl; preferably the group A is substituted or unsubstituted pyridyl claim 1 , or pyridyl fused with benzene or morpholine ring claim 1 , the fused benzene or morpholine ring being unsubstituted or substituted with methyl.3. The compounds according to claim 2 , wherein the Calkyl is methyl claim 2 , the Calkoxy is methoxy claim 2 , the Calkoxycarbonyl is methoxycarbonyl claim 2 , and/or the Calkylamido is pentylamido .4. The compound according to claim 3 , wherein the Rgroup is cyano.5. The compound according to claim 1 , wherein the compound is:3-(furan-2-ylmethyl)-4-hydroxy-1,3-thiazinane-2-thione (compound 1);2-(methoxycarbonyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 2);2-cyanoethyl(furan-2-ylmethyl)dithiocarbamate (compound 3);3-(furan-2-ylmethyl)-4-hydroxy-4,5-dimethyl-3,4-dihydro-2H-1,3-thiazine-2-thione (compound 4);2-sulfamoylethyl(furan-2-ylmethyl)dithiocarbamate (compound 5);2-boronoethyl(furan-2-ylmethyl)dithiocarbamate (compound 6);2-(methylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 7);2-(benzylsulfinyl)ethyl(furan-2-ylmethyl)dithiocarbamate (compound 8);4-hydroxy-3-(pyridin-3-ylmethyl)-1,3-thiazinane-2-thione ( ...

Подробнее
30-05-2013 дата публикации

BENZENE, PYRIDINE, AND PYRIDAZINE DERIVATIVES

Номер: US20130137686A1
Принадлежит:

Disclosed are compounds and pharmaceutically acceptable salts of Formula I 2. A compound according to claim 1 , wherein Qis C—R.3. A compound according to claim 1 , wherein Xis N.46-. (canceled)9. A compound according to claim 8 , wherein Xis N.10. A compound according to claim 9 , wherein{'sub': 3', '4', '1', 'Z1, 'claim-text': [{'sub': '1', 'Zis —O— or —NH—;'}, {'sub': Z1', '1', '14', '22', '2, 'claim-text': {'sub': Z1', '1', '10', '1', '10', '2', '10', '2', '10', '1', '6', '2', '1', '6', '2', '2', '2', '1', '6', '2', '2', '1', '6', '2', '1', '6', '2', '10', '2', '10', '1', '10', '1', '10', '23, 'wherein Ris optionally substituted at any available position with C-Calkyl, C-Chaloalkyl, C-Calkenyl, C-Calkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH, —S—(C-C)alkyl, —SO—(C-C)alkyl, —SONH, —SONH—(C-C)alkyl, —SONH-aryl, —SO-aryl, —SO—(C-C)alkyl, —SO-aryl, C-Calkoxy, C-Calkenyloxy, C-Calkynyloxy, mono- or di-(C-C)alkylamino, —OC-Calkyl-Z, or R.'}, 'Ris a C-Calkyl group where up to five of the carbon atoms in the alkyl group are optionally replaced independently by R, carbonyl, ethenyl, ethynyl or a moiety selected from N, O, S, SO, or SO, with the proviso that two O atoms, two S atoms, or an O and S atom are not immediately adjacent each other,'}], 'Rand Rare independently hydrogen, halo, or —ZR, wherein'}11. A compound according to claim 9 , wherein{'sub': '4', 'Ris H; and'}{'sub': 3', '1', 'Z1, 'claim-text': [{'sub': '1', 'Zis —O— or —NH—;'}, {'sub': Z1', '1', '14', '22', '2, 'claim-text': {'sub': Z1', '1', '10', '1', '10', '2', '10', '2', '10', '1', '6', '2', '1', '6', '2', '2', '2', '1', '6', '2', '2', '1', '6', '2', '1', '6', '2', '10', '2', '10', '1', '10', '1', '10', '23, 'wherein Ris optionally substituted at any available position with C-Calkyl, C-Chaloalkyl, C-Calkenyl, C-Calkynyl, hydroxy, carboxy, carboxamido, oxo, halo, amino, cyano, nitro, —SH, —S—(C-C)alkyl, —SO—(C-C)alkyl, —SONH, —SONH—(C—O)alkyl, —SONH-aryl, —SO-aryl, —SO—(C-C ...

Подробнее
30-05-2013 дата публикации

4-carboxybenzylamino derivatives as histone deacetylase inhibitors

Номер: US20130137690A1
Принадлежит: Individual

The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the 4-carboxybenzylamino derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the 4-carboxybenzylamino derivatives in vivo.

Подробнее
30-05-2013 дата публикации

HETEROARYL-PYRAZOLE DERIVATIVE

Номер: US20130137865A1
Принадлежит: TAISHO PHARMACEUTICAL CO., LTD.

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like. 3. The compound or a pharmaceutically acceptable salt thereof according to , wherein in the formula [I] , ring A represents a phenyl group or a 6-membered heteroaryl group (wherein the phenyl group or 6-membered heteroaryl group is substituted with 1 to 3 substituents selected from the group consisting of —SONRR , —SOR , —NRSOR , a Calkyl group , an amino group , and a halogen atom , and R , R , R , Rand Rare as defined in ).4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': 1', 'f', 'f, 'sub': 2', 'n1', '2', 'n2', '2', 'n3', '2', 'n4', '2', 'n5', '2', 'n6', '2', 'n7', '2', 'n8', '2', 'n9, 'claim-ref': [{'@idref': 'CLM-00001', 'claim 1'}, {'@idref': 'CLM-00002', '2'}], 'Yrepresents —(CH)—, —(CH)—NR—(CH)—, —(CH)—O—(CH)—, —(CH)—NHC(═O)—(CH)—, —(CH)—C(═O)NH—(CH)—, ethynylene, piperazin-1,4-yl, phenylene, pyridylene, or 5-membered heteroarylene (wherein Rand n1 to n9 are as defined in or ), and'}{'sup': '2', 'sub': 1-6', '3-6', '1-6', '1-6', '3-6', '1-6, 'Yrepresents a phenyl group, a naphthyl group, a pyridyl group, a quinolyl group, or a partially saturated condensed polycyclic heteroaryl group {wherein the phenyl group, naphthyl group, pyridyl group, quinolyl group, or partially ...

Подробнее
06-06-2013 дата публикации

Novel hydroxamates as therapeutic agents

Номер: US20130142758A1
Принадлежит: Pharmacyclics LLC

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Подробнее
06-06-2013 дата публикации

NOVEL COMPOUNDS

Номер: US20130143870A1
Принадлежит:

This invention relates to compounds of formula I 3. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant claim 1 , diluent and/or carrier.4. A method of treating schizophrenia claim 1 , schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses claim 1 , post stroke dementia claim 1 , deficits in concentration claim 1 , mild cognitive impairment claim 1 , the cognitive dysfunction in Alzheimers disease or the cognitive dysfunction of schizophrenia comprising administering to a patient a therapeutically effective amount of a compound according to . This invention relates to substituted pyrazoles and their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment.Glutamate is the primary excitatory amino acid in the mammalian central nervous system. Neurotransmission mediated by glutamate has been demonstrated to be critical in many physiological processes, such as synaptic plasticity, long term potentiation involved in both learning and memory as well as sensory perception (Riedel et al., Behav. Brain Res. 2003, 140:1-47). Furthermore, it has been demonstrated that an imbalance of glutamate neurotransmission plays a critical role in the pathophysiology of various neurological and psychiatric diseases.The excitatory neurotransmission of glutamate is mediated through at least two different classes of receptors, the ionotropic glutamate receptors (NMDA, AMPA and kainate) and the metabotropic glutamate receptors (mGluR). The ...

Подробнее
06-06-2013 дата публикации

PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS

Номер: US20130143879A1
Принадлежит: GENKYOTEX SA

The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). 2. The method according to claim 1 , wherein said disease or condition is selected from atherosclerosis claim 1 , endothelial dysfunction claim 1 , hypertension claim 1 , cardiovascular complications of Type I or Type II diabetes claim 1 , intimal hyperplasia claim 1 , coronary heart disease claim 1 , cerebral claim 1 , coronary or arterial vasospasm claim 1 , heart failure including congestive heart failure claim 1 , peripheral artery disease claim 1 , restenosis claim 1 , trauma caused by a stent claim 1 , stroke claim 1 , ischemic attack claim 1 , vascular complications such as after organ transplantation claim 1 , myocardial infarction claim 1 , hypertension claim 1 , formation of atherosclerotic plaques claim 1 , platelet aggregation claim 1 , angina pectoris claim 1 , aneurysm claim 1 , aortic dissection claim 1 , ischemic heart disease claim 1 , cardiac hypertrophy claim 1 , pulmonary embolus claim 1 , thrombotic events including deep vein thrombosis claim 1 , injury caused after ischemia by restoration of blood flow or oxygen delivery as in organ transplantation claim 1 , open heart surgery claim 1 , angioplasty claim 1 , hemorrhagic shock claim 1 , angioplasty of ischemic organs including heart claim 1 , brain claim 1 , liver claim 1 , kidney claim 1 , retina and bowel claim 1 , bronchial asthma claim 1 , bronchitis claim 1 , allergic rhinitis claim 1 , adult respiratory syndrome claim 1 , cystic fibrosis claim 1 , lung viral infection (influenza) claim 1 , pulmonary hypertension claim 1 , idiopathic pulmonary fibrosis claim 1 , chronic obstructive pulmonary diseases (COPD) claim 1 , hay fever claim 1 , asthma claim 1 , obesity claim 1 , metabolic syndrome claim 1 , Type II diabetes ...

Подробнее
06-06-2013 дата публикации

4-[2-[ [5-METHYL-1-(2-NAPHTALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL] MORPHOLINE SALTS

Номер: US20130143884A1
Принадлежит:

The present invention relates to 4-[-2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salts, specifically to the hydrochloride, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of sigma receptor associated diseases. 1. A 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salt selected from the group consisting of ethanesulfonate , fumarate , hydrochloride , malate , maleate , malonate and methanesulfonate.2. The 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine salt according to wherein the salt is the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine.3. A process for the preparation of the hydrochloride salt of claim 2 , comprising:a) mixing 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine and a solution containing hydrochloric acid, andb) isolating the resulting hydrochloride salt.4. A pharmaceutical composition comprising the hydrochloride salt of and a pharmaceutically acceptable carrier claim 2 , adjuvant claim 2 , or vehicle.5. A process for the manufacture of a medicament comprising the step of combining the hydrochloride salt of with a pharmaceutically acceptable carrier claim 2 , adjuvant or vehicle.6. A method of treating and/or preventing a sigma receptor mediated disease in a patient comprising administering to the patient in need of such a treatment a therapeutically effective amount of the hydrochloride salt of so as to treat and/or prevent the disease.7. The method according to wherein the disease is diarrhoea; lipoprotein disorders; migraine; obesity; arthritis; hypertension; arrhythmia; ulcer; learning claim 6 , memory and attention deficits; cognition disorders; neurodegenerative diseases; demyelinating diseases; addiction to drugs and chemical substances including cocaine claim 6 , amphetamine claim 6 , ethanol and nicotine; tardive diskinesia; ischemic stroke; epilepsy; ...

Подробнее
06-06-2013 дата публикации

Stem cell differentiating agents and uses therefor

Номер: US20130143935A1
Принадлежит: University of Texas System

The present invention relates to screens for compounds that can induce stem cell differentiation. In addition, isoxazoles and sulfonyl hydrazones are identified as general classes of compounds that can induce differentiation of stem cells into cells of neuronal and cardiac fate, respectively.

Подробнее
06-06-2013 дата публикации

FUNGICIDAL PYRAZOLES

Номер: US20130143940A1
Принадлежит: E I DU PONT DE NEMOURS AND COMPANY

Disclosed are compounds of Formula 1 and Formula 1A including all stereoisomers, N-oxides, and salts thereof, 2. A compound of wherein:{'sup': 1', '3a, 'Qis a phenyl ring substituted with 1 to 3 substituents independently selected from R;'}{'sup': 2', '3a', '3a', '3b, 'Qis a phenyl ring substituted with 1 to 3 substituents independently selected from R; or a pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrazinyl or pyrimidinyl ring, each ring optionally substituted with up to 3 substituents independently selected from Ron carbon atom ring members and Ron nitrogen atom ring members;'}{'sup': '1', 'sub': 1', '2', '2', '2, 'Ris C-Calkyl, —CHF, —CHCl or cyclopropyl;'}{'sup': '2', 'sub': 1', '2', '2', '4', '2', '3', '1', '2', '1', '2, 'Ris H, halogen, cyano, C-Calkyl, C-Calkenyl, halomethyl, cyanomethyl, hydroxymethyl, C-Calkoxyalkyl, C-Calkoxy or C-Chaloalkoxy;'}{'sup': '3a', 'sub': 1', '2', '1', '2', '1', '2', '1', '2', '2', '3, 'each Ris independently halogen, cyano, C-Calkyl, C-Chaloalkyl, cyclopropyl, C-Calkoxy, C-Calkylthio, C-Calkylcarbonyl or —U—V-T;'}{'sup': '3b', 'sub': 1', '2', '2', '3, 'each Ris independently cyano, C-Calkyl, cyclopropyl or C-Calkoxyalkyl;'}{'sup': 4', '7, 'Ris Br, Cl, F, —ORor —SC≡N;'}{'sup': '5', 'Ris H or methyl;'}{'sup': 7', '1', '9, 'sub': 1', '3', '2', '6', '1', '3', '2', '3', '2', '6', '2, 'Ris H, C-Calkyl, C-Calkenyl, C-Chaloalkyl, cyclopropyl, C-Ccyanoalkyl, C-Calkoxyalkyl, —S(═O)OMor —C(═W)R;'}{'sup': '9', 'Ris methyl or methoxy;'}{'sup': '10', 'each U is independently O, N(R) or a direct bond;'}{'sup': '10', 'each Ris independently H or methyl;'}{'sub': 1', '3, 'each V is independently C-Calkylene, wherein up to 1 carbon atom is selected from C(═O);'}{'sup': 11a', '11b', '12, 'each T is independently N(R)(R) or OR;'}{'sup': 11a', '11b, 'each Rand Ris independently H or methyl;'}{'sup': '12', 'sub': 1', '6', '1', '6, 'each Ris independently H, C-Calkyl or C-Chaloalkyl;'}W is O; and{'sup': '1', 'Mis Na or K.'}3. A compound of ...

Подробнее
13-06-2013 дата публикации

3-(Fluorovinyl)pyrazoles and their use

Номер: US20130150325A1
Принадлежит: Bayer Intellectual Property GmbH

The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures. 6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. A pharmaceutical composition comprising a compound as defined in in combination with one or more inert claim 1 , non-toxic claim 1 , pharmaceutically suitable auxiliary substances.12. A pharmaceutical composition comprising a compound as defined in in combination with one or more other active compounds.13. (canceled)14. (canceled)15. A method for the treatment and/or prevention of a cancer disease or tumour disease comprising administering to a human or animal in need thereof an effective amount of at least one compound as defined in .16. A method for the treatment and/or prevention of ischaemic cardiovascular diseases claim 1 , cardiac insufficiency claim 1 , cardiac infarction claim 1 , arrhythmia claim 1 , stroke claim 1 , pulmonary hypertension claim 1 , fibrotic diseases of the kidney and lung claim 1 , psoriasis claim 1 , diabetic retinopathy claim 1 , macular degeneration claim 1 , rheumatic arthritis claim 1 , or Chugwash polycythaemia comprising administering to a human or animal in need thereof an effective amount of at least one compound as defined in . The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular ...

Подробнее
13-06-2013 дата публикации

THERAMUTEIN MODULATORS

Номер: US20130150358A1
Автор: Housey Gerard M.
Принадлежит: HMI MEDICAL INNOVATIONS, LLC.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein. 2. The method of wherein Xis N.3. The method of wherein Xis N.5. The method of wherein Xis N.6. The method of wherein Xis N.8. The method of wherein Xis N.9. The method of wherein Xis N.11. The method of wherein Xis N.12. The method of wherein Xis N.14. The method of wherein Xis N.15. The method of wherein Xis N.18. The method of wherein Xis N.19. The compound of wherein Xis N.21. The method of wherein Xis N.22. The method of wherein Xis N.24. The method of wherein Xis N.25. The method of wherein Xis N.27. The method of wherein Xis N.28. The method of wherein Xis N.30. The method of wherein Xis N.31. The method of wherein Xis N.33. The method of wherein Xis N.34. The method of wherein Xis N.36. The compound of wherein Xis N.37. The compound of wherein Xis N.52. A method for determining whether a substance is an inhibitor or an activator of a theramutein which is capable of eliciting a detectable phenoresponse claim 36 , which comprises:a) incubating a first cell which expresses the theramutein at a substantially constant level with the substance;b) incubating a second cell which expresses a corresponding prototheramutein at a substantially constant level with a known inhibitor or activator of the prototheramutein;c) comparing a phenoresponse of the second cell to the known inhibitor or activator of the prototheramutein to the phenoresponse of the first cell to the substance; andd) determining that the phenoresponse of the first cell is inhibited or activated to at least the same ...

Подробнее
13-06-2013 дата публикации

4-[-2-[[5-METHYL-1-(2-NAPHTALENYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE HYDROCHLORIDE AMORPHOUS SOLID FORMS

Номер: US20130150575A1
Принадлежит: LABORATORIOS DEL DR. ESTEVE, S.A.

The present invention relates to solid forms having a low degree of crystallinity or substantially amorphous of the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine (P027) and processes for their preparation. 110-. (canceled)11. A solid form of hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine having a degree of crystallinity below 30%.12. The solid form according to claim 11 , which is substantially amorphous.13. The solid form according to claim 12 , having a FTIR spectrum showing characteristic peaks at about: 3421 claim 12 , 3137 claim 12 , 3054 claim 12 , 2959 claim 12 , 2859 claim 12 , 2540 claim 12 , 2447 claim 12 , 1632 claim 12 , 1600 claim 12 , 1557 claim 12 , 1509 claim 12 , 1487 claim 12 , 1442 claim 12 , 1372 claim 12 , 1305 claim 12 , 1290 claim 12 , 1256 claim 12 , 1236 claim 12 , 1199 claim 12 , 1169 claim 12 , 1130 claim 12 , 1100 claim 12 , 1046 claim 12 , 1013 claim 12 , 982 claim 12 , 933 claim 12 , 917 claim 12 , 861 claim 12 , 819 claim 12 , and 748 cm.14. A process for preparing a solid form according to claim 11 , the process comprising:a) dissolving the hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine in a suitable solvent or mixture of solvents, andb) evaporating the solvent or mixture of solvents.15. The process according to claim 14 , wherein said dissolving is performed at a temperature ranging from about room temperature to 120° C.16. The process according to claim 14 , wherein said evaporating of the solvent or mixture of solvents is performed at a temperature of about room temperature or above.17. The process according to claim 14 , wherein the solvent or mixture of solvents is selected from the group consisting of: water claim 14 , acetonitrile claim 14 , isopropanol claim 14 , methanol claim 14 , acetonitrile-water claim 14 , isopropanol-water claim 14 , and methanol-water.18. A process for preparing ...

Подробнее
20-06-2013 дата публикации

TRICYCLIC NECROSTATIN COMPOUNDS

Номер: US20130158024A1
Принадлежит:

The present invention features compounds, pharmaceutical compositions, and methods for treating trauma, ischemia, stroke, degenerative diseases associated with cellular necrosis, and other conditions. Screening assays for identifying compounds useful for treating these conditions are also described. 2. The Nec-3 compound of claim 1 , wherein said Nec-3 compound is a substantially pure (3R claim 1 ,3aR)-rel isomer claim 1 ,or a pharmaceutically acceptable salt thereof.3. The Nec-3 compound of claim 2 , wherein Ris —C(O)R claim 2 , and Ris substituted Calkyl claim 2 ,or a pharmaceutically acceptable salt thereof.4. The Nec-3 compound of claim 2 , wherein said Nec-3 compound is a substantially pure (3R claim 2 ,3aR)-enantiomer claim 2 ,or a pharmaceutically acceptable salt thereof.5. The Nec-3 compound of claim 2 , wherein said Nec-3 compound is a substantially pure (3S claim 2 ,3aS)-enantiomer claim 2 ,or a pharmaceutically acceptable salt thereof.6. The Nec-3 compound of claim 2 , wherein{'sub': '2', 'the bond indicated by (a) is a double bond; Z is CH; and'}{'sub': 1', '2', '4', '6', '7', '10', '11, 'each of R, R, R, R, R, R, and R, independently, represents hydrogen,'}or a pharmaceutically acceptable salt thereof.7. The Nec-3 compound of claim 6 , wherein{'sub': '8', 'Ris H,'}or a pharmaceutically acceptable salt thereof.8. The Nec-3 compound of claim 2 , wherein{'sub': 3', '5', '2', '9, 'Rrepresents methoxyl; Rrepresents C(O)CHOH; and Rrepresents alkoxy of one to six carbon atoms,'}a pharmaceutically acceptable salt thereof.10. The Nec-3 compound of claim 9 , wherein said Nec-3 compound is a substantially pure (3R claim 9 ,3aR)-enantiomer claim 9 ,or a pharmaceutically acceptable salt thereof.11. The Nec-3 compound of claim 9 , wherein said Nec-3 compound is a substantially pure (3S claim 9 ,3aS)-enantiomer claim 9 ,or a pharmaceutically acceptable salt thereof.12. A pharmaceutical composition comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(i) the ...

Подробнее
20-06-2013 дата публикации

Sigma receptor inhibitors

Номер: US20130158029A1
Принадлежит: Laboratorios del Dr Esteve SA

The invention refers to compounds of general formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.

Подробнее
20-06-2013 дата публикации

HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS

Номер: US20130158075A1
Принадлежит: Piramal Enterprises Limited

The present invention relates to heterocyclic compounds of formula 1, in all their stereoisomeric and tautomeric forms; and their pharmaceutically acceptable salts, solvates, polymorphs, prodrugs, carboxylic acid isosteres and N-oxides. The invention also relates to processes for the manufacture of the heterocyclic compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1. The present invention further provides a method of treatment of such diseases or disorders by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof. 167-. (canceled)89. A compound according to claim 68 , wherein A is an aryl and said aryl is unsubstituted or substituted with one or more groups selected from halogen claim 68 , hydroxy claim 68 , (C-C)-alkoxy claim 68 , cyano claim 68 , (C-C)-alkyl claim 68 , OCF claim 68 , CF claim 68 , (C-C)-cycloalkyl claim 68 , aryl claim 68 , aryloxy claim 68 , heterocyclyl claim 68 , or O-heterocyclyl.90. A compound according to claim 68 , wherein A is an aryl group and said aryl group may be fused with an unsubstituted or substituted 5 or 6-membered cycloalkyl ring optionally containing one or more heteroatoms selected from O claim 68 , N or S.91. A compound according to claim 68 , wherein A is a heterocyclyl and said heterocyclyl is unsubstituted or substituted with one or more groups selected from halogen claim 68 , hydroxy claim 68 , (C-C)-alkoxy claim 68 , cyano claim 68 , (C-C)-alkyl claim 68 , (C-C)-cycloalkyl claim 68 , aryl claim 68 , aryloxy claim 68 , heterocyclyl or O-heterocyclyl.92. A compound according to claim 68 , wherein A is a (C-C)-cycloalkyl and said (C-C)-cycloalkyl is unsubstituted or substituted with one or more groups selected from halogen claim 68 , hydroxy ...

Подробнее
27-06-2013 дата публикации

CANNABINOID RECEPTOR MODULATORS

Номер: US20130165412A1
Принадлежит:

The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease. 156.-. (canceled)58. The compound according to claim 57 , wherein:{'sup': 1', '6, 'sub': 1', '6, 'Rand Rare each independently selected from: H, and C-Calkyl; and'}{'sup': 2', '3', '4', '5, 'R, R, R, and Rare each H.'}59. The compound according to claim 57 , wherein R claim 57 , R claim 57 , R claim 57 , R claim 57 , R claim 57 , and Rare each H.60. The compound according to claim 57 , wherein X is NRand Y is CC(O)N(R)R.61. The compound according to claim 57 , wherein X is CC(O)N(R)Rand Y is NR.62. The compound according to claim 57 , wherein Ris selected from: C-Calkyl claim 57 , aryl claim 57 , C-Ccycloalkyl claim 57 , heteroaryl claim 57 , heterocyclyl claim 57 , and hydroxyl; wherein said C-Calkyl claim 57 , aryl claim 57 , and heteroaryl are each optionally substituted with one or two ...

Подробнее
27-06-2013 дата публикации

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Номер: US20130165443A1
Принадлежит:

Compounds of the formula I: 2. The compound of claim 1 , wherein R claim 1 , Rand Rare hydrogen.3. The compound of claim 2 , wherein Ris phenyl substituted at the 4-position with methyl or halo and optionally substituted at the 2-position with halo.4. The compound of claim 2 , wherein Ris 4-methyl-phenyl.5. The compound of claim 2 , wherein Ris pyridin 2-yl substituted with methyl or halo at the 5-position.6. The compound of claim 2 , wherein Ris 5-methyl-pyridin-2-yl.8. The compound of claim 7 , wherein Ris hydrogen.9. The compound of claim 7 , wherein Ris methyl.10. The compound of claim 7 , wherein Ris: Calkyl; Calkyloxy-Calkyl; hydroxy-Calkyl; Calkylsulfanyl-Calkyl; Calkylsulfonyl-Calkyl; amino-Calkyl; N—Calkyl-amino-Calkyl; N claim 7 ,N-di-Calkyl-amino-Calkyl; Ccycloalkyl; optionally substituted phenyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.11. The compound of claim 7 , wherein Ris: Calkyloxy-Calkyl; hydroxy-Calkyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.12. The compound of claim 7 , wherein Ris methoxymethyl.13. The compound of claim 7 , wherein Ris hydroxymethyl.14. The compound of claim 7 , wherein Ris heteroaryl selected from pyridinyl claim 7 , pyrimidinyl claim 7 , or pyrazinyl claim 7 , each of which may be optionally substituted once or twice with methyl.15. The compound of claim 7 , wherein Ris hydroxymethyl claim 7 , methoxymethyl claim 7 , pyrazin-2-yl or 5-methyl-pyrazin-2-yl.16. The compound of claim 7 , wherein Ris Calkyl claim 7 , Ccycloalkyl or Ccycloalkyl-Calkyl.17. The compound of claim 7 , wherein Ris isopropyl claim 7 , isobutyl or tert butyl.18. The compound of claim 1 , wherein said compound is selected from:4-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;5-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Furan-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Thiophene-2- ...

Подробнее
27-06-2013 дата публикации

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

Номер: US20130165492A1
Принадлежит: ALLERGAN, INC.

The present invention provides a compound, that is 1. A compound , that is a 1-[(5-halo or alkyl or fluoroalkyl or alkoxy-2-{(cycloalkyl or substituted cycloalkyl)oxy}phenyl)methyl]-(5-alkyl or fluoroalkyl)-1H-pyrazole-3-(carboxylic acid or methylene carboxylic acid) or an alkyl or aryl ester or sulfonamide thereof.2. A compound , that is a 1-[(5-halo or alkyl or fluoroalkyl or alkoxy-2-{(cycloalkyl)oxy}phenyl)methyl]-(5-alkyl or fluoroalkyl)-1H-pyrazole-3-(carboxylic acid or methylene carboxylic acid) or an alkyl or aryl ester or sulfonamide thereof.3. A compound according to wherein said compound is a 1-({5-halo-2-[(2-cycloalkyl)oxy]phenyl}methyl)-3-carboxylic acid or ester or sulfonamide thereof.4. A compound according to wherein said compound is a 1-({5-halo-2-[(2-cycloalkyl)oxy]phenyl}methyl)-3-carboxylic acid.5. A compound according to wherein said ester or sulfonamide is an alkyl ester or sulfonamide.6. A compound according to claim 3 , wherein said halo is selected from the group consisting of chloro and bromo.8. The compound of wherein Ris selected from the group consisting of carbocyclic aryl and alkyl.9. The compound of wherein Ris OH.10. The compound of wherein Ris selected from the group consisting of alkyl and chloro and bromo-substituted alkyl.11. The compound of wherein Ris H.12. The compound of wherein Y is absent.13. The compound of wherein Z is O.14. The compound of wherein W is cyclopentyl15. The compound of that is selected from the group consisting of1-(5-Chloro-2-cyclopentylmethoxy-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid,1-(5-Bromo-2-cyclopentylmethoxy-benzyl)-5-methyl-1H-pyrazole-3-carboxylic acid and1-(5-bromo-2-cyclobutylmethoxy-benzyl)-5-methyl-1h-pyrazole-3-carboxylic acid17. The method of wherein Ris OH.18. The method compound of wherein Ris selected from the group consisting of carbocyclic aryl and alkyl19. The method of wherein W is cycloalkyl.20. The method of wherein Ris selected from the group consisting of alkyl and chloro ...

Подробнее
27-06-2013 дата публикации

Preparing 5-Fluoro-1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carbaldehydes

Номер: US20130165664A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a novel process for preparing 5-fluoro-1-alkyl-3-fluoro-1-alkyl-1H-pyrazole-4-carbonyl chlorides, a useful intermediate in the manufacture of fungicides. 14-. (canceled)6. The compound of formula (IV) according to where Rrepresents methyl claim 5 , ethyl claim 5 , n-propyl claim 5 , isopropyl claim 5 , butyl claim 5 , pentyl and Rrepresents CFH claim 5 , CF claim 5 , CFCl claim 5 , CCF claim 5 , CF claim 5 , or CF.7. The compound of formula (IV) according to claim 5 , where Rrepresents methyl and Rrepresents CFH or CF.8. 5-Fluoro-1-methyl-3-difluoromethyl-1H-pyrazole-4-carbaldehyde.10. (canceled) The present application claims priority to U.S. Provisional Patent Application No. 61/262,641, filed Nov. 19, 2009, which is hereby incorporated by reference in its entirety.The present invention relates to a novel process for preparing 5-fluoro-1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carbonyl chlorides, a useful intermediate in the manufacture of fungicides.Pyrazolecarbonyl chlorides are important synthons for preparing crop protection actives. Pyrazolecarbonyl chlorides are typically prepared by reacting carboxylic acids with a chlorinating agent. One advantage of this method is that appropriate carboxylic acids are easy to obtain and hence available on an industrial scale. This prerequisite is not satisfied in the case of the preparation of substituted pyrazolecarbonyl chlorides, since the corresponding carboxylic acids are not readily available.It has now been found that 5-fluoro-1-alkyl-2-fluoroalkyl-1H-pyrazole-4-carbonyl chlorides of formula (I)where Rrepresents C-C-alkyl and Rrepresents C-C-fluoroalkyl, are obtained when 5-chloro-1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carbaldehyde of formula (II)where Rand Rare each as defined above, is initially reacted (step 1) with a fluorinating agent of formula (III)MF  (III)where M represents Li, Na, K, Cs, AlkN (where Alk represents C-C-alkyl),and optionally in the presence of a phase transfer ...

Подробнее
27-06-2013 дата публикации

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

Номер: US20130165665A1
Принадлежит: ALLERGAN, INC.

The present invention provides a compound that is represented by the following general formula 1. A compound , that is a -[(2-{(hydrocarbyl or substituted hydrocarbyl)oxa , thia , sulfinyl , sulfonyl or alkylenyl}phenyl)methyl]-(5-hydro or alkyl or fluoroalkyl)-1H-pyrazole-3-(oxaacetic acid or azaacetic acid or thiaacetic acid) or an alkyl or aryl ester or sulfonamide thereof2. The compound of claim 1 , that is a 1-[(2-{(hydrocarbyl)oxa}phenyl)methyl]-(5-alkyl)-1H-pyrazole-3-(oxaacetic acid) or an alkyl or aryl ester or sulfonamide thereof3. The compound of claim 1 , wherein said hydrocarbyl is selected from the group consisting of alkyl and carbocyclic aryl.4. The compound of claim 3 , wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl and phenyl.5. The compound of claim 4 , wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl having from 4 to 7 carbons.6. The compound of claim 1 , wherein said compound is a 1H-pyrazole-3-oxaacetic acid compound or lower alkyl ester thereof.7. The compound of claim 6 , wherein said compound is a 5-alkyl-1H-pyrazole.8. The compound of claim 6 , wherein said phenyl is a bromophenyl.9. The compound of claim 1 , wherein said compound is a 5-alkyl-1H-pyrazole-3-oxaacetic acid compound or lower alkyl ester thereof claim 1 , said hydrocarbyl is selected from the group consisting of branched chain alkyls having from 4 to 7 carbons and said phenyl is a bromophenyl.10. The compound of claim 1 , that is selected from the group consisting of:{1-[5-Chloro-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-3-yloxy}-acetic acid;{1-[5-Chloro-2-(4-chloro-benzyloxy)-benzyl]-5-methyl-1H-pyrazol-3-yloxy}-acetic acid;{1-[5-Bromo-2-(2-ethyl-butoxy)-benzyl]-5-methyl-1H-pyrazol-3-yloxy}-acetic acid; and,{1-(5-Chloro-2-isobutoxy-benzyl)-5 -methyl-1H-pyrazol-3-yloxy}-acetic acid.12. The compound of claim 11 , wherein Ris selected from the group consisting of carbocyclic aryl and alkyl.13. The ...

Подробнее
27-06-2013 дата публикации

COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

Номер: US20130165666A1
Принадлежит: ALLERGAN, INC.

The present invention provides a compound that is represented by the following general formula 1. A compound , that is a 1-[(5-halo or alkyl or fluoroalkyl or alkoxy-2-{(hydrocarbyl or substituted hydrocarbyl)oxy}phenyl)methyl]-(3 or 5 alkyl or fluoroalkyl)-1H-pyrazole-4-(carboxylic acid or methylene carboxylic acid) or an alkyl or aryl ester or sulfonamide thereof.2. The compound of wherein said halo is selected from the group consisting of chloro and bromo.3. The compound of wherein said hydrocarbyl is selected from the group consisting of alkyl and carbocyclic aryl.4. The compound of wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl and phenyl.5. The compound of wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl having from 4 to 7 carbons.6. The compound of wherein said compound is a 1-[(5-Chloro or bromo-or trifluoromethyl-2-{hydrocarbyloxy}phenyl)methyl]-(3 or 5 methyl)-1H- pyrazole-4-carboxylic acid.7. The compound of wherein said hydrocarbyl is selected from the group consisting of alkyl and carbocyclic aryl.8. The compound of wherein said hydrocarbyl is selected from the group consisting of branched chain alkyl and phenyl.9. The compound of wherein said hydrocarbyl a branched chain alkyl having from 4 to 7 carbons.10. The compound of that is selected from the group consisting of:1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-methylenecarboxylic acid;1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-5-methyl-1H-pyrazole-4-carboxylic acid;1-[(5-Bromo-2-{2-ethylbutyloxy}phenyl)methyl]-3-methyl-1H-pyrazole-4-carboxylic acid;1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-1H-pyrazole-4-carboxylic acid;1-[(5-Chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3,5-dimethyl-1H-pyrazole-4-carboxylic acid;1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-3-propyl-1H-pyrazole-4-carboxylic acid;1-[(5-chloro-2-{2-ethylbutyloxy}phenyl)methyl]-5-propyl-1H-pyrazole-4-carboxylic acid;1-[(5- ...

Подробнее
27-06-2013 дата публикации

METHOD FOR THE PREPARATION OF PHOSPHINE BUTADIENE LIGANDS, COMPLEXES THEREOF WITH COPPER AND USE THEREOF IN CATALYSIS

Номер: US20130165667A1
Принадлежит:

A method for the creation of a carbon-carbon (C—C) bond or of a carbon-heteroatom (C-HE) bond includes reacting a compound carrying a leaving group with a nucleophilic compound carrying a carbon atom or a heteroatom (HE) capable of replacing the leaving group, thus creating a C—C or C-HE bond, in which process the reaction is carried out in the presence of an effective amount of a catalytic system comprising at least one copper/butadienylphosphine complex. 1. A method for the creation of a carbon-carbon (C—C) bond or of a carbon-heteroatom (C-HE) bond by reacting a compound carrying a leaving group with a nucleophilic compound carrying a carbon atom or a heteroatom (HE) capable of replacing the leaving group , thus creating a C—C or C-HE bond , in which process the reaction is carried out in the presence of an effective amount of a catalytic system comprising at least one copper/butadienylphosphine complex.3. The method as claimed in claim 1 , in which the Rand Rsubstituents of the butadienylphosphine of formula (1) are identical and each represent a radical chosen independently from alkyl claim 1 , aryl claim 1 , heteroaryl claim 1 , monoalkylamino claim 1 , dialkylamino claim 1 , alkoxy claim 1 , aryloxy and heteroaryloxy.4. The method as claimed in claim 1 , in which the Rand/or Rsubstituents can be connected so as to form claim 1 , with the carbon atom which carries them claim 1 , a carbocyclic or heterocyclic group having from 3 to 20 carbon atoms which is saturated claim 1 , unsaturated claim 1 , monocyclic or polycyclic claim 1 , in the latter case comprising two or three rings claim 1 , it being possible for the adjacent rings to be aromatic in nature.5. The method as claimed in claim 1 , in which the butadienylphosphine of formula (1) is of Z configuration or of E configuration or is in the form of a mixture in all proportions of the Z and E configurations.6. The method as claimed in claim 1 , in which the butadienylphosphine of formula (1) exhibits the ...

Подробнее
04-07-2013 дата публикации

Dihydropyrazoles

Номер: US20130172351A1
Принадлежит: Merck Patent GmBH

Novel dihydropyrazole derivatives of formula (I) 2. The compound according to claim 1 , wherein R claim 1 , L denote Ar.3. The compound according to claim 1 , wherein{'sup': 1', '2', '3', '4, 'X, X, X, Xdenote a single bond, and'}m denotes 0.4. The compound according to claim 1 , wherein{'sup': 1', '1', '2, 'Ardenotes an aromatic, monocyclic carbocycle having 5-8 C atoms, which is mono-, di- or trisubstituted by at least one substituent selected from the group of Rand R.'}5. The compound according to claim 1 , wherein{'sup': '1', 'Hetdenotes an unsaturated or aromatic monocyclic heterocycle having 3-6 C atoms and 1-3 N, O and/or S atoms, which is substituted by at least one substituent selected from the group of Hal, A and OA.'}9. A pharmaceutical composition comprising at least one compound according to and/or a physiologically acceptable salt thereof.10. The pharmaceutical composition according to claim 9 , comprising pharmaceutically tolerable adjuvants for oral administration.11. The pharmaceutical composition according to claim 9 , comprising at least a second active pharmaceutical ingredient.13. The method according to claim 12 , wherein an effective amount of at least one compound and/or a physiologically acceptable salt thereof is administered to a mammal in need of treating fertility disorders. This application claims the benefit of U.S. Provisional application Ser. No. 61/503,694 filed on Jul. 1, 2011, which is hereby incorporated by reference.The present invention relates to compounds of formula (I)wherein L, R, R, R, R, R, R, X, X, X, X, Y, m and n have the meaning according to the claims, and/or physiologically acceptable salts thereof. The compounds of formulas (I) can be used as positive allosteric modulators of the follicle stimulating hormone receptor (FSHR). Objects of the invention are also pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) for the treatment of fertility disorders. ...

Подробнее